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Pharmaceutical patents represent some of the most valuable
intellectual property assets in the world: they can be worth billions
of dollars if courts uphold their validity and find them infringed.
But, if invalidated, generic drug manufacturers can get to market
earlier, generating billions of dollars of revenue for themselves and
creating enormous savings for consumers. Accordingly, drug
patents are the product of careful, high-cost prosecution and are
associated with high-stakes, bet-the-company litigation.
But women lawyers are noticeably absent from pharmaceutical
patent practice. This article reports an original empirical
study finding that women comprise only one-third of the top
pharmaceutical patent litigators and only one-quarter of lawyers who
prosecute litigated pharmaceutical patents—numbers far below
the share of women in the legal profession overall. The usual
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explanation for any lack of representation in patent practice is the
“pipeline” problem—that is, an insufficient number of women in
the technical fields underlying patent law. But our study finds
little support for any pipeline problem. Indeed, recent studies
indicate that more women law students have scientific
undergraduate and graduate degrees than their male counterparts.
Interestingly, the gender gap among pharmaceutical patent
lawyers does not carry over to public sector work. The U.S. Patent
and Trademark Office is the one place where our study finds
anything close to parity: 42.3% of pharmaceutical patent
examiners are women and 57.7% are men. This finding adds to a
nascent literature documenting vast disparities in gender
representation in the private versus public sectors, both in patent
law and in law practice more generally.
It also suggests that the lack of women doing patent law in
private practice in the pharmaceutical field probably is not due to
any pipeline problem; instead, it likely stems from structural
inequalities that permeate the highest levels of corporate law firms.
Those firms, as well as their pharmaceutical company clients, all
say that diversity is important. But, as our study shows, there is
a disconnect between rhetoric and reality. Fully solving structural
inequality in law practice is a formidable task, but this article
sketches a few ways in which firms and their clients could help
create a patent bar that is more diverse and inclusive.
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INTRODUCTION
Pharmaceutical patents are among the most valuable
intellectual property assets in the world.1 Obtaining and enforcing
drug patents is a big business and is an area where clients expect
their law firms to have high billable hours. This is because drug
companies earn billions of dollars a year on each blockbuster drug,
so a decision on whether or not a profitable product is protected by

1. See Arti K. Rai, Saurabh Vishnubhakat, Jorge Lemus & Erik Hovenkamp, PostGrant Adjudication of Drug Patents: Agency and/or Court?, 37 BERKELEY TECH. L.J. (forthcoming)
(manuscript at 3), https://ssrn.com/abstract=3865804 (“[F]ew areas of technology can
match [the biopharmaceutical industry]. Particularly . . . for small-molecule drugs . . . a
billion-dollar drug monopoly may be protected from competition by a relatively small
number of patents.”).
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a patent has huge ramifications.2 For example, Eli Lilly laid off a
large chunk of its sales staff when its antidepressant Cymbalta went
off patent at the end of 2013.3 And Merck cut almost a third of its
workforce after the loss of patent protection on its asthma
medication Singulair.4 Indeed, the entire cost of a patent litigation
can amount to just a single day’s worth of sales.5
The litigation stakes are high. Winning a pharmaceutical patent
case can result in billion-dollar verdicts for the brand manufacturer
or years of additional market exclusivity.6 For example, in 2013,
Pfizer won a $2.15 billion patent infringement judgment against
generic drug makers Teva and Sun,7 one of the largest patent damage
awards in U.S. history.8 But a loss by the brand manufacturer can

2. For critical commentary on drug prices and industry profits, see generally
Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition:
Hearing Before the S. Comm. on the Judiciary, 116th Cong. (2019); Examining the Actions of Drug
Companies in Raising Prescription Drug Prices: Hearing Before the H. Comm. on Oversight &
Reform, 116th Cong. (2019); Aaron S. Kesselheim et al., The High Cost of Prescription Drugs in
the United States: Origins and Prospects for Reform, 316 JAMA 858, 860–63 (2016) (noting that
patents are the primary reason for high drug prices and blaming manufacturers for using
“product life-cycle management” to extend the life of patents); I-MAK, AMERICA’S
OVERSPEND: HOW THE PHARMACEUTICAL PATENT PROBLEM IS FUELING HIGH DRUG PRICES,
(Oct. 2017), https://www.i-mak.org/wp-content/uploads/2020/10/Excess-Costs-BriefingPaper-FINAL-2017-10-24-with-cover-rev.compressed.pdf. But see Johnathan Darrow,
Debunking the “Evergreening” Patents Myth, HARV. L. REC., Dec. 8, 2010, at 6 (discussing how
the lag time between filing a patent application and Food and Drug Administration (FDA)
approval can dramatically shorten periods of market exclusivity).
3. Lilly’s Sales-Force Restructuring to Affect 1,600-Plus, INDIANAPOLIS BUS. J. (May 6, 2013),
https://www.ibj.com/articles/41201-lilly-s-sales-force-restructuring-to-affect-1-600-plus.
4. Tracy Staton, 10 Largest U.S. Patent Losses, FIERCE PHARMA (Oct. 24, 2011, 8:35 PM),
https://www.fiercepharma.com/special-report/merck-10-largest-u-s-patent-losses.
5. AbbVie’s Humira, for instance, had $20 billion in sales in 2021—or $550 million per day.
Leading Drugs Worldwide Based on Projected 2021 Sales, STATISTA, https://www.statista.com/
statistics/973523/top-drugs-by-year-on-year-sales-increase.
6. See Aaron Stiefel, 10 Years Later—Impact of eBay on Patent Injunctions in the Life
Sciences, ARNOLD & PORTER (June 21, 2016), https://www.arnoldporter.com/en/
perspectives/publications/2016/06/2016_06_21_10_years_later_impact_of_ebay_13037.
7. Pfizer Inc. v. Teva Pharms. U.S.A., Inc., 882 F. Supp. 2d 643, 671 (D. Del. 2012).
8. Indeed, three of the top five largest patent damage awards in U.S. history
were in pharmaceutical cases. See Top 10 Largest Patent Infringement Awards, GREYB,
https://www.greyb.com/largest-patent-infringement-awards. The other two were Gilead Sciences.,
Inc. v. Merck & Co., 888 F.3d 1231 (Fed. Cir. 2018), in which a jury awarded $2.54 billion but the
patents were later found invalid by the Federal Circuit, and Centocor Orth Biotech v. Abbott
Laboratories, 636 F.3d 1341 (Fed. Cir 2011), in which the Federal Circuit reversed a $1.67 billion
damages award.
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allow generic companies to get to market early, earn their own share
of profits, and save consumers billions of dollars.9
Procuring a drug patent at the U.S. Patent & Trademark Office
(USPTO) in the first place is a similarly high-stakes endeavor
because drug patents are ex ante known to be valuable.10 Drafting a
pharmaceutical patent often requires post-graduate education as
well as years of experience in patent drafting.11 Though much has
been written about the breadth, vagueness, and questionable
validity of many of the software- and computer-related patents
asserted by so-called patent trolls,12 drug patents are much
different.13 Because they are crucial to market success, companies
put much effort into careful prosecution to ensure the patents
withstand any later challenge to their validity.14
Because pharmaceutical patent practice is among the most highstakes and complex types of commercial law practice, it provides an
important context in which to examine the demographics of the legal
profession. In the empirical study presented in this Article, we
consider questions about gender equality—or, more accurately, the
9. See Generic Drugs and Low-Cost Prescriptions, FED. TRADE COMM’N,
https://www.consumer.ftc.gov/articles/0063-generic-drugs-and-low-cost-prescriptions (noting
that generic drugs cost 20 to 70% less than their branded counterparts).
10. For summaries of the patent prosecution process, see S. Sean Tu, Patenting Fast and
Slow: Examiner and Applicant Use of Prior Art, 38 CARDOZO ARTS & ENT. L.J. 391, 395–99 (2020);
Naira Rezende Simmons, Putting Yourself in the Shoes of a Patent Examiner: Overview of the
United States Patent and Trademark Office (USPTO) Patent Examiner Production (Count) System,
17 J. MARSHALL REV. INTELL. PROP. L. 32, 33 (2017).
11. See infra Section II.A.
12. See, e.g., Mark A. Lemley & A. Douglas Melamed, Missing the Forest for the Trolls,
113 COLUM. L. REV. 2117, 2126 (2013); Paul R. Gugliuzza, Patent Trolls and Preemption, 101 VA.
L. REV. 1579, 1580 (2015). Patent trolls, or, less pejoratively, non-practicing entities (NPEs),
do not sell any products or provide any services; they exist for the sole purpose of enforcing
patents. For an analysis of the heterogeneity among patentees typically tagged with the NPE
moniker, see Christopher A. Cotropia et al., Unpacking Patent Assertion Entities (PAEs), 99
MINN. L. REV. 649, 654 (2014).
13. See generally Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L.
REV. 1575, 1675 (2003) (discussing the different characteristics of innovation—and
patentability and infringement—across various technological sectors).
14. See Dani Kass, Patent Specification Concerns Make IPRs Tricky for Drug Cos.,
LAW360 (Jan. 28, 2022, 8:46 PM), https://www.law360.com/ip/articles/1458065/patentspecification-concerns-make-iprs-tricky-for-drug-cos (“Drug patents tend to hold high
value for their companies, which means taking out a singular patent may have more of an
impact than it would in the technology world. Companies also work harder to make sure
drug patents are bulletproof from the outset . . . . ‘There’s a lot of effort put into these.
Excellent counsel. Excellent disclosures. Excellent considerations of everything put into
the claims.’”).
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lack thereof—in pharmaceutical patent examination, prosecution,
and litigation. This study builds on other recent work documenting
gender inequality in patent law practice.15 And it adds to a growing
literature examining why—after decades of formal equality under
the law—women are still markedly underrepresented in the
corporate world.16
One oft-mentioned explanation (or, perhaps, “justification”) for
the dearth of women in patent practice is that women tend not to
have the science and technology backgrounds that are essential to
work in the field.17 The pharmaceutical sector is an interesting
context in which to examine this supposed “pipeline” problem
because the evidence suggests that it should be relatively minor—
as data we have collected indicates, today, women obtain a
majority of the biological science undergraduate and graduate
degrees issued in the United States, as well as a majority of
chemistry undergraduate degrees and 40–45% of chemistry
graduate degrees.18
This study first reviews the backgrounds of every examiner at
the USPTO involved in an abbreviated new drug application
(ANDA) patent from 2005 through 2021. It then reviews every
pharmaceutical patent involved in infringement litigation between
2009 and 2021 that terminated in a final decision on the merits
undertaken by lawyers hailing from the top five law firms
representing brand pharmaceutical companies and the top five law
firms representing generic pharmaceutical companies. We proceed
to review the practitioners associated with those specific patents:
(1) the patent prosecutors who helped the brand pharmaceutical
15. Paul R. Gugliuzza & Rachel Rebouché, Gender Inequality in Patent Litigation, 100
N.C. L. REV. 1683 (2022).
16. See, e.g., NAOMI CAHN, JUNE CARBONE & NANCY LEVIT, SHAFTED: WHY WOMEN
LOSE IN A WINNER-TAKE-ALL WORLD (forthcoming), https://wwws.law.northwestern.edu/
research-faculty/events/colloquium/law-gender/documents/2021_sp_cahn_shafted_
introduction.pdf; Naomi Cahn, June Carbone & Nancy Levit, Gender and the Tournament:
Reinventing Antidiscrimination Law in an Age of Inequality, 96 TEX. L. REV. 425, 471 (2018);
Jennifer L. Berdahl et al., Work as a Masculinity Contest, 74 J. SOC. ISSUES 422, 423 (2018); see
also Claire Cain Miller, Women Did Everything Right. Then Work Got ‘Greedy,’ N.Y. TIMES (Apr.
26, 2019), https://www.nytimes.com/2019/04/26/upshot/women-long-hours-greedyprofessions.html.
17. See John Murph, Minority in IP: Navigating a Lonely Road, WASH. LAW., Mar.–Apr.
2022, at 26 (discussing the “glaring racial and gender disparities in STEM (science,
technology, engineering, and mathematics) related to the professional fields.”).
18. See infra Section I.B.1.
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companies obtain the patents and (2) the patent litigators who
represented both the brand and generic pharmaceutical companies
who litigated the cases to a final decision on validity.
We find that women are noticeably absent from both
pharmaceutical patent prosecution and litigation. Specifically, of
the 217 patent prosecutors in our dataset who worked on
pharmaceutical patents that were eventually litigated to a final
decision on the merits by one of the select firms, 75.1% are men and
only 24.9% are women.19 Likewise, of the 333 patent litigators in our
dataset who litigated pharmaceutical patents on the merits from
one of the select firms, 62.5% are men and only 37.5% are women.20
These gaps are surprising because studies also find that women
are overrepresented in many of the undergraduate and graduate
school fields associated with the pharmaceutical industry.21
Furthermore, women represent a majority of law students who
have the scientific educational backgrounds that can be helpful
when litigating or prosecuting drug patents.22 Indeed, the
(comparatively few) female patent prosecutors and litigators who
appear in our dataset tend to have higher levels of education
overall as compared to their male counterparts.23
Our study finds that the only place where we see anything close
to parity between women and men in the pharmaceutical patent
area is among examiners at the USPTO, where women represent
42.3% of the examiners in the most relevant technology center and
men represent 57.7%.24 This finding in particular adds to an
emerging literature showing that gender inequality—though it
remains prevalent throughout the legal profession25—is less
pronounced in government legal work than in the private sector,
particularly in the field of pharmaceutical patent law.26
19. See infra Section IV.A.2.
20. See infra Section IV.B.
21. See infra Section I.B.1.
22. See infra Section I.B.2.
23. See infra Section IV.C.
24. See infra Section IV.A.1.
25. See Women in the Profession, AM. BAR ASS’N, https://www.americanbar.org/groups/
diversity/women.
26. Gugliuzza & Rebouché, supra note 15, 1713 fig. 13 (showing that women working
for the government argued approximately the same number of cases as men at the Federal
Circuit), 1718 fig. 18 (showing that women conducted approximately 50% of the oral
arguments by the USPTO Solicitor’s Office at the Federal Circuit).
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The remainder of this Article proceeds as follows. In Part I, we
outline the problem of gender inequality in the legal profession,
examine the role of education in patent practice, and provide
statistics on the gender composition of the pool of people with
undergraduate and graduate degrees in the fields that are relevant
to pharmaceutical patent law. In Part II, we review the legal
requirements to become a patent agent or patent attorney, describe
the field of patent law practice, and summarize the process of
pharmaceutical patent litigation. In Part III, we describe the novel
datasets we created for this study. In Part IV, we discuss our results
on the participation of women in patent law practice, analyzing
whether there is a gender disparity among examiners at the USPTO
as well as among lawyers who assist clients prosecuting
pharmaceutical patents. Additionally, we examine the
participation of women who litigate drug patents, both on the
brand and generic sides, at top law firms. Finally, in Part V, we
sketch some possible solutions to the gender inequality in patent
law that our study documents.
I. WOMEN IN SCIENCE AND THE “PIPELINE” PROBLEM
Today, women are well represented in the sciences at the
undergraduate and graduate levels as well as in the work force. In
fact, in life sciences and health-related jobs, women represent 48%
and 74% of the workforce, respectively.27 Additionally, in the
biological and life sciences, the average annual salary for women
actually exceeds that of men: $68,000 for women and $65,000 for
men.28 This is especially striking because women make an average
of 84% of their male counterparts’ salaries across all professions. 29

27. Richard Fry et al., STEM Jobs See Uneven Progress in Increasing Gender, Racial and
Ethnic Diversity, PEW RSCH. CTR. (Apr. 1, 2021) https://www.pewresearch.org/science/
2021/04/01/stem-jobs-see-uneven-progress-in-increasing-gender-racial-and-ethnic-diversity.
28. See Women, Minorities, and Persons with Disabilities in Science and Engineering, NAT’L
SCI. FOUND. (2019), https://www.nsf.gov/statistics/wmpd [hereinafter 2019 NSF Study].
29. Id. ($76,000 median salary for women versus $90,000 median salary for men). The
U.S. Census Bureau has recently shown that women still make approximately 18–20% less
than men at the median. Thomas B. Foster, Marta Murray-Close, Liana Landivar & Mark
deWolf, An Evaluation of the Gender Wage Gap Using Linked Survey and Administrative Data 8
fig. 1 (U.S. Census Bureau, Working Paper No. CES-20-34, 2020). Among the other sciences
relevant to pharmaceutical patents, the data in the physical sciences (which includes
chemistry) shows greater inequality, with average annual salaries of $60,000 for women and
$78,000 for men. Id.
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Women’s parity in representation and salary in some fields of
science, however, does not translate to the legal profession.30
Women’s representation began increasing in the legal profession in
the 1970s, but the United States has lagged well behind other
countries.31 While women made up 50% of the legal profession in
countries like Romania and Poland by the mid-2000s, they had
reached only the 30% mark in the United States by that point.32
Today, women comprise nearly half of all associates in private
law practice (and over half of all summer associates).33 Yet only
about 38% of attorneys at the largest U.S. law firms are women, and
23% of law firm equity partners are women.34 Furthermore,
although women start at relatively equal levels of pay, the wage
gap quickly increases when women are promoted to non-equity as
well as equity partners. Though some studies find that women
lawyers work more hours on average than men, women are still
represented in top positions far below their rate of representation
in the legal profession overall.35
In the remainder of this Part, we dig more deeply into the data
on gender representation in patent law in the pharmaceutical field,
first discussing the supposed “pipeline” problem, then presenting
evidence debunking that explanation for gender inequality in
patent practice in the pharmaceutical field, and finally linking our
evidence to data on women in the legal profession more broadly.

30. See JOYCE STERLING & LINDA CHANOW, IN THEIR OWN WORDS: EXPERIENCED
WOMEN LAWYERS EXPLAIN WHY THEY ARE LEAVING THEIR LAW FIRMS AND THE PROFESSION,
AM. BAR ASS’N (2021), https://www.americanbar.org/content/dam/aba/administrative/
women/intheirownwords-f-4-19-21-final.pdf.
31. Ethan Michelson, Women in the Legal Profession, 1970–2010: A Study of the Global
Supply of Lawyers, 20 IND. J. GLOB. L. STUD. 1071, 1075 (2013).
32. Id. at 1083.
33. James Leipold, NALP UPDATE: THE LEGAL EMPLOYMENT MARKET 6, 9 (2022) (on
file with authors) (reporting that 48.2% of associates are women).
34. Jacqueline Bell, Law360’s Glass Ceiling Report: What You Need to Know, LAW360
(Sept. 13, 2021, 3:03 PM), https://www.law360.com/appellate/articles/1418221/law360-sglass-ceiling-report-what-you-need-to-know.
35. Gabe Friedman, Harvard Study: Women Lawyers Work More Than Men, BLOOMBERG
LAW (May 12, 2015), https://news.bloomberglaw.com/business-and-practice/harvardstudy-women-lawyers-work-more-than-men (discussing a time series study of Harvard Law
School graduates).

145

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

12/10/22 7:14 PM

BRIGHAM YOUNG UNIVERSITY LAW REVIEW

48:1 (2022)

A. Patent Law’s Pipeline Problem
Previous studies have shown that women are generally
underrepresented in the patent system.36 Women not only lack
representation as inventors,37 there is also a lack of gender diversity
among the lawyers who prosecute patents. Women comprise only
17% of the attorneys registered to practice at the USPTO.38 Further,
women account for only 12% of total attorney appearances in the
important new post-issuance proceedings at the USPTO’s Patent
Trial and Appeal Board (PTAB), which began operating in 2012.39
36. Gugliuzza & Rebouché, supra note 15; Annette I. Kahler, Examining Exclusion in
Woman-Inventor Patenting: A Comparison of Educational Trends and Patent Data in the Era of
Computer Engineer Barbie, 19 AM. U. J. GENDER SOC. POL’Y & L. 773 (2011); Saurabh
Vishnubhakat, Gender Diversity in the Patent Bar, 14 J. MARSHALL REV. INTELL. PROP. L. 67
(2014); Mary T. Hannon, The Patent Bar Gender Gap: Expanding the Eligibility Requirements to
Foster Inclusion and Innovation in the U.S. Patent System, 10 IP THEORY 1 (2020).
37. Until recently, after urging by Congress, the USPTO had not collected
demographic information on patentees. A recent study by the USPTO used statistical
analysis to analyze historical rates of patents granted by gender and found that women
represented only 12% of named inventors. U.S. PAT. & TRADEMARK OFF., PROGRESS AND
POTENTIAL: A PROFILE OF WOMEN INVENTORS ON U.S. PATENTS 4 (Feb. 2019),
https://www.uspto.gov/sites/default/files/documents/20190502_PPAC_Progress-andPotential.pdf [hereinafter PROGRESS AND POTENTIAL]. The USPTO found that in 1980 only 7%
of patents had at least one woman listed as an inventor; this figure increased to 21% by 2016.
Id. at 3. Another study found that over the nearly 40-year period between 1976 and 2013, the
rate of women patenting increased from 2.7% to 10.8%. Cassidy Sugimoto, Chaoqun Ni, Jevin
West & Vincent Larivière, The Academic Advantage: Gender Disparities in Patenting, 10 PLOS
ONE 1 (2015). Furthermore, these patenting rates are similar for every country represented
in USPTO patent applications. Id. fig. 1. Interestingly, women inventors are concentrated
around certain technologies. Specifically, women are most represented in biotechnology
(25% invention rate), pharmaceuticals (23% invention rate), and organic fine chemistry (21%
invention rate). Id. Correspondingly, the female share of patent inventors is highest among
chemical and pharmaceutical companies. PROGRESS AND POTENTIAL, supra, at 10 (showing
that the three companies with the highest rates of women inventorship are all chemical and
pharmaceutical companies: Procter and Gamble (24%), Bristol-Myers Squibb (24%) and
Abbott Laboratories (21%)). This rate, however, still seems low considering that women
represent nearly 50% of biological and life scientists.
38. Vishnubhakat, supra note 36, at 79.
39. PTAB BAR ASS’N, WOMEN AT THE PTAB: POST-GRANT PROCEEDINGS 3 (2021),
https://www.ptabbar.org/docs/2021_PTAB_Bar_Report_on_Women_at_the_PTAB.pdf.
In 2012, the USPTO, through the PTAB, started a new form of post-issuance proceedings.
The new proceedings are designed mainly to give parties in patent infringement suits a
quicker and cheaper route to challenge the validity of the patents they are accused of
infringing. The proceedings have been enormously popular—the USPTO has received over
10,000 petitions for review in the first eight years of their existence. J. Jonas Anderson & Paul
R. Gugliuzza, Federal Judge Seeks Patent Cases, 71 DUKE L.J. 419, 460 (2021). For a detailed
overview of the new procedures, see Rochelle Cooper Dreyfuss, Giving the Federal Circuit a
Run for Its Money: Challenging Patents in the PTAB, 91 NOTRE DAME L. REV. 235, 242–49 (2015).
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Many commentators have described the root cause of patent
law’s lack of gender diversity as a pipeline problem.40 Specifically,
the upstream lack of women with science, technology, engineering,
and mathematics (STEM) degrees creates the downstream problem
of fewer women with STEM-related jobs, including the practice of
patent law.
As we discuss in more detail below,41 being a member of the
patent bar is required to assist clients with prosecuting patents
before the USPTO, and, generally speaking, one cannot participate
patent prosecution without a science degree or equivalent
training.42 Additionally, one cannot become a patent examiner
without a science degree. Finally, while lawyers can litigate patents
without a science degree, it is often helpful to have a science degree
to understand the technology at issue during litigation.
Because of these educational prerequisites, proponents of the
pipeline argument contend that the diversity problem could be
fixed simply by increasing the rate at which women graduate in
STEM fields.43 This would increase the upstream supply of women
with STEM degrees, and we would then see more women
becoming patent attorneys downstream. Equality would be
reached as older male lawyers age into retirement and are replaced
by a cohort of lawyers who have near gender parity. The problem
would, in other words, fix itself if given the time; there would

40. See, e.g., Elaine Spector & LaTia Brand, Diversity in Patent Law: A Data Analysis of
Diversity in the Patent Practice by Technology Background and Region, AM. BAR ASS’N (Sept. 16,
2020),
https://www.americanbar.org/groups/intellectual_property_law/publications/
landslide/2020-21/september-october/diversity-patent-law-data-analysis-diversity-patentpractice-technology-background-region (“[P]atent law requires a hard science degree. As
such, the pipeline with respect to diverse candidates entering a STEM field needs to be
addressed.”); Emily Collins, Gender Inequality—How Many Patent Offices Does It Take to Fix a
Leaky Pipeline?, KILBURN & STRODE (Mar. 6, 2020), https://www.kilburnstrode.com/
knowledge/in-house/gender-inequality; Esther H. Lim, Breaking Down Barriers, INTELL.
PROP. MAG. (Mar. 27, 2020), https://www.finnegan.com/en/insights/articles/CDMRbreaking-down-barriers.html (“Targeted outreach to high school and undergraduate
students about STEM, and careers in IP, will help fill the pipeline of future women and
diverse attorneys.”). For a general discussion of the pipeline problem, see CAROLINA
ACADEMIC PRESS, THE EDUCATION PIPELINE TO THE PROFESSIONS: PROGRAMS THAT WORK TO
INCREASE DIVERSITY (Sarah E. Redfield ed., 2012).
41. See infra Section II.A.
42. For a scholarly critique of the requirements imposed for admission to the patent
bar, see William Hubbard, Razing the Patent Bar, 59 ARIZ. L. REV. 383 (2017).
43. See the sources quoted supra note 40.
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be no need to further scrutinize the issue of discrimination in
professional life.
But phrasing the matter as a pipeline problem oversimplifies
the issue. As the empirical study presented below makes plain,
simply increasing the number of women in the United States with
scientific degrees will not solve the gender diversity problem in
patent law in the pharmaceutical field because women are already
heavily represented in the sciences relevant to pharmaceutical
patent practice—and they have been for a while.
Accordingly, the problem goes deeper than the supply chain.
The patent field, as well as private sector law firms generally, need
to address embedded structural barriers and systematic biases
before gender equality is achieved. As we describe later in the
Article,44 it will be necessary for law firms, clients, and courts to
take active steps to achieve these goals because the problem will
not solve itself by simply educating women in STEM fields.
B. Women Science Majors at Undergraduate, Graduate, and
Law Schools
Education is a springboard to both STEM jobs as well as legal
jobs that require a scientific background. According to a recent
survey, today, women in the United States earn a majority of all
undergraduate and advanced college degrees (58%) and also
represent a majority of all STEM college degrees (53%).45 In this
section, we show that, when it comes to the sciences most relevant
to pharmaceutical patent practice, women are well-represented—
indeed, arguably overrepresented—at the undergraduate and
graduate levels and among law students in the United States.
Accordingly, the pharmaceutical patent sector provides an
excellent context in which to assess whether any pipeline problem
could really be solved if more women simply graduated with the
relevant degrees.
1. Undergraduate and Graduate Degrees
A 2019 study conducted by the National Science Foundation
(NSF) found that, over the past decade, women attending U.S.

44. See infra Part V.
45. See Fry et al., supra note 27.
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universities have been awarded a majority of the degrees in
biological sciences at all degree levels—bachelor’s, master’s, and
doctorate.46 Likewise, women have received a majority of
bachelor’s degrees in chemistry. Though men still receive a
majority of graduate degrees in chemistry, the numbers are close.
That is to say, women are arguably overrepresented in the fields of
study that are most associated with pharmaceutical drug patents.
Specifically, 49,262 (60%) and 78,568 (63%) of biological sciences
bachelor’s degrees were awarded to women in 2008 and 2018,
respectively. Similarly, 5,611 (59%) and 10,358 (60%) of master’s
degrees in biological sciences were awarded to women in 2008 and
2018, respectively. Finally, 3,707 (51%) and 4,308 (53%) of doctorate
degrees in biological sciences were awarded to women in 2008 and
2018, respectively.
Likewise, 5,909 (50.0%) and 7,588 (50.8%) of chemistry
bachelor’s degrees were awarded to women in 2008 and 2018,
respectively. Though men still received a majority of graduate
degrees in chemistry, the proportions are relatively close: 1,116
(45.4%) and 1,035 (46.3%) of master’s degrees in chemistry were
awarded to women in 2008 and 2018, respectively. And 901 (36.1%)
and 1,193 (39.0%) of doctorate degrees in chemistry were awarded
to women in 2008 and 2018, respectively.

46. 2019 NSF study, supra note 28.
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Figure 1: Percentage of Women with Degrees in Biological
Sciences or Chemistry
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2. Law Schools
Over half of law students in the United States today are
women;47 that number has been over 40% since the 1980s and has
increased in the decades since to gender parity.48 However, given
the topic of this Article, one might wonder the extent to which
women with science degrees are attending law school. To address
this question, we collected data from the Law School Admissions
Counsel (LSAC), which is the organization through which most
candidates apply to law school.49
LSAC’s data on undergraduate majors is self-reported and is
sorted by year. Dual degrees are counted as two separate degrees.
47. See Elizabeth Olson, Women Make Up Majority of U.S. Law Students for First Time,
N.Y. TIMES (Dec. 16, 2016), https://www.nytimes.com/2016/12/16/business/dealbook/
women-majority-of-us-law-students-first-time.html.
48. Janet Taber et al., Gender, Legal Education, and the Legal Profession: An Empirical
Study of Stanford Law Students and Graduates, 40 STAN. L. REV. 1209, 1209 (1988) (providing
general statistics on gender representation in law schools and the legal profession); see also
LSAC, Current Volume Summaries by Region, Race/Ethnicity, Gender Identity & LSAT Score,
https://www.lsac.org/data-research/data/current-volume-summaries-regionraceethnicity-gender-identity-lsat-score (LSAC 2008 application data showing applicant
ratios of 40,486 (49%) women and 41,687 (51%) men; LSAC 2018 application data showing
applicant ratios of 32,488 (54%) women and 27,508 (46%) men).
49. LSAC kindly provided us with applicant and matriculant undergraduate major data.

150

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

151

12/10/22 7:14 PM

Overqualified and Underrepresented

Applicants who apply in multiple years are included in all years
(these duplicates are not removed). Most relevant for our purpose,
LSAC aggregates majors into “health professions” and “natural
sciences” categories. From 2001–2020 there were a total of 4,703
(63.0%) women and 2,728 (36.6%) men in the health professions and
19,741 (46.4%) women and 22,629 (53.2%) men with degrees in
natural sciences who matriculated to law schools.50 The proportions
of applicants with health professions and natural science degrees
were largely the same.51
Overall, only a small minority of law students have backgrounds
in the sciences. For example, in 2020, approximately 3,689 students
with natural science majors52 applied to law school—less than 5% of
the total applicant pool. Although the undergraduate GPAs for
natural science majors are about equivalent to other majors, the
LSAT scores for natural science majors are significantly higher than
other majors.53
Figure 2 shows the percentage of women who attended law
schools from 2001–2020 with undergraduate degrees in either
health or natural sciences.54

50. Numbers do not add up to 100% because some applicants do not indicate their sex
as part of the LSAC application.
51. From 2001–20 there were 10,414 (63.7%) women and 5,862 (35.8%) men with health
professions degrees. Additionally, from 2001–20 there were 39,918 (45.7%) women and
37,665 (53.9%) men with natural science degrees who applied to law schools.
52. Natural sciences include majors such as: biology, chemistry, biochemistry zoology,
and biophysics among others—all of which would make a student eligible for admission to
the patent bar. See infra Section II.A.
53. The mean and median GPA scores for natural science majors are 3.29 and 3.34,
respectively. The mean and median GPA scores for all majors are 3.31 and 3.38, respectively. The
mean and median LSAT scores for natural science majors are 157.99 and 158.40, respectively. The
mean and median LSAT scores for all majors are 154.62 and 154.67, respectively.
54. Health professions include majors such as: health (kinesiology), health care
administration, nursing, premedical (medicine), dietetics/nutritional science, speech
pathology/audiology, pharmacy, radiology, animal sciences, physical therapy, dentistry,
and occupational therapy. Although most health professions majors are not classified under
Category A for patent bar eligibility, most health professions majors would likely qualify
under Category B. See infra Section II.A.
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Figure 2: Percentage of Women Law Students with Degrees in
Natural Sciences or Health
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Despite few law students with scientific backgrounds, the data
above makes plain that women are very close to equally
represented among law students who have majors associated with
pharmaceutical patent practice. Accordingly, we would expect to
see women represented at parity or even slightly higher than men
in an area of law practice, like patent law, associated with those
very degrees. However, as our empirical study shows, this is not
the case.
C. Women in the Legal Job Market
Today, women and men enter the legal profession in equal
numbers and initially make roughly the same amount, billing the
same number of hours, at approximately the same billing rates.55
However, a gap develops as women move from associates to nonequity and equity partners. Although women bill the same number

55. DESTINY PEERY, NATIONAL ASSOCIATION OF WOMEN LAWYERS 2019 SURVEY REPORT
PROMOTION AND RETENTION OF WOMEN IN LAW FIRMS (2019) [hereinafter 2019
NAWL STUDY].
ON THE
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of hours, they are paid less, and their billing rates are significantly
lower than similarly situated male partners.
Women are also largely absent in the upper echelon of law firm
leadership. Specifically, according to a 2019 survey conducted by
the National Association of Women Lawyers (NAWL), 47% of
associates are women, but only 30% of non-equity partners and
only about 20% of equity partners are women.56 The gap increases
when looking at women of color. Specifically, less than 4% of
partners are women of color, even though they comprise 15% of
all associates.57
Similar to the overall wage gap, the NAWL survey found that
the average male law firm associate makes $12,272 more than the
average female associate.58 At the associate level, women make 94%
of their male counterparts.59 Compensation, however, greatly
diverges at the partner level. The average non-equity female
partner makes only 89% as much as a non-equity male partner
(non-equity male partners make $40,566 more per year than female
non-equity partners).60 At the equity level, male partners make, on
average, $109,491 more than female partners.61 Female equity
partners make only 88% as much as the average male
equity partner.62
Interestingly, at least according to the NAWL survey, there is
no substantial difference in the billable hours recorded by men and
women “at different levels and in different roles.”63 Furthermore,
the survey indicates that associate billing rates start out relatively

56. Elaine Spector & LaTia Brand, Diversity in Patent Law: A Data Analysis of Diversity in the
Patent Practice by Technology Background and Region, 13 LANDSLIDE, Sept.–Oct. 2020, at 1,
https://www.americanbar.org/groups/intellectual_property_law/publications/landslide/202021/september-october/diversity-patent-law-data-analysis-diversity-patent-practice-technologybackground-region.
57. DESTINY PEERY, PAULETTE BROWN & EILEEN LETTS, LEFT OUT AND LEFT BEHIND:
THE HURDLES, HASSLES, AND HEARTACHES OF ACHIEVING LONG-TERM LEGAL CAREERS FOR
WOMEN OF COLOR at v (2018).
58. 2019 NAWL STUDY, supra note 55, at 4.
59. Id. (showing that the mean male associate makes $204,082 versus the mean female
associate, who makes $191,810).
60. Id. at 5.
61. Id. at 6.
62. Id.
63. Id. at 4.
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similar but diverge when they reach the partner level.64 Male nonequity partners bill at an hourly rate about 5.5% higher than female
non-equity partners.65
Overall, these studies show that women enter private law
practice in numbers roughly equal to men. However, women are
not promoted or paid at a rate equal to men, and the wage
disparities grow as associates move up the ladder to partner. We
show next how these inequalities are replicated in the field of
pharmaceutical patent law.
II. PATENT PROSECUTION AND LITIGATION
Patent prosecution and patent litigation are specialized fields of
law practice. In this Part of the Article, we describe the educational
and licensing requirements required to practice at the USPTO and
to litigate patent cases in federal court. We also describe the existing
literature on the demographics of patent lawyers and summarize
the basic processes of pharmaceutical patent prosecution
and litigation.
A. Requirements for Patent Prosecutors and Patent Litigators
Patent prosecution is the process by which a patent agent or
patent attorney helps an inventor get a patent by “prosecuting” the
patent application at the USPTO. Passing the patent bar is required
to prosecute patents, and there are educational requirements to sit
for the patent bar exam.66 One need not be a lawyer to take the
patent bar; a non-lawyer who passes the patent bar is admitted as
a patent agent.
To qualify to take the patent bar, a candidate needs to show “the
required scientific and technical training.”67 The most common way
of meeting the requisite scientific and technical qualification is to
be classified as satisfying the requirements for “Category A” by the
USPTO. Category A can be met by having a bachelor’s, master’s, or
64. Id. (showing that at the associate level men bill at an average of $441 per hour while
women bill $425 per hour).
65. Id. at 5.
66. See U.S. PAT. & TRADEMARK OFF., GENERAL REQUIREMENTS BULLETIN FOR ADMISSION
TO THE EXAMINATION FOR REGISTRATION TO PRACTICE IN PATENT CASES BEFORE THE UNITED
STATES PATENT AND TRADEMARK OFFICE 3–8 (2021). Under certain circumstances, former patent
examiners can waive the examination requirement.
67. Id. at 3.
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doctoral degree in a recognized technical subject from an accredited
U.S. college or university or an equivalent bachelor’s degree from a
foreign university.68 Category A fields of study include biology,
computer science, chemistry, physics, and engineering. However,
not all fields are created equal.69 For example, not all computer
software degrees qualify as Category A; some computer software
degrees require additional accreditation.70
The patent bar exam tests an applicant’s knowledge of patent
laws, rules, and procedures as set out in the Manual of Patent
Examination Procedure. Only upon passing the examination does the
applicant receive a USPTO registration number, which allows the
patent practitioner to represent others before the USPTO in
patent matters.
During the patent application process, on the other side of the
negotiating table from the prosecutor are patent examiners. Patent
examiners represent the USPTO and review the patent application
to make sure that all requirements for patentability are met. In
general, a patent must recite eligible subject matter,71 be novel72 and
nonobvious,73 and describe the invention in an appropriate level of
detail.74 Patent examiners and patent agents or attorneys work
together to help inventors obtain a patent. The requirements to be
a patent examiner are a minimum of a bachelor’s degree in
engineering or science and to be a U.S. citizen.75 Patent examiners
do not need to pass the patent bar, but they undergo a four-month

68. See id.
69. Id.
70. See id. The USPTO states that “acceptable Computer Science degrees must be
accredited by the Computer Science Accreditation Commission (CSAC) of the Computing
Science Accreditation Board (CSAB), or by the Computing Accreditation Commission (CAC)
of the Accreditation Board for Engineering and Technology (ABET), on or before the date
the degree was awarded.”
71. 35 U.S.C. § 101.
72. Id. § 102.
73. Id. § 103.
74. Id. § 112. For more on the requirements of patentability, see S. Sean Tu, Patenting
Fast and Slow: Examiner and Applicant Use of Prior Art, 38 CARDOZO ARTS & ENT. L J. 391 (2020)
and S. Sean Tu, Patenting Fast and Slow: Examiner Rejections and Applicant Traversals to NonPrior Art Rejections, 2021 MICH. ST. L. REV. 411 (2021).
75. U.S. PAT. & TRADEMARK OFF., AMERICA’S INNOVATION AGENCY (2021),
https://www.uspto.gov/sites/default/files/documents/USPTOPatentExaminerInfograp
hicAPPLYNOW1.pdf.
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residency at the Patent Training Academy before joining their
permanent division.76
In contrast to patent prosecution, patent litigation is the process
by which an attorney either sues someone for patent infringement
or defends a client from a patent infringement suit. Patent litigators
can represent clients in various legal matters and thus must have a
law degree. They must also be licensed to practice within the
federal courts in the relevant state.77 Most states require a juris
doctor (J.D.) from a law school accredited by the American Bar
Association before being able to sit for the state bar, which is
usually a requirement to practice within the federal courts of that
state. While it is certainly advantageous for patent litigators to have
a scientific degree or a technical background, it is not required or
necessary. Indeed, many partners in law firms litigating patent
cases do not have a science background.78
B. Women in Patent Prosecution
Women are poorly represented among patent prosecutors. One
study reviewed 47,228 registered patent practitioners and found
that women made up only 21.8% of prosecutors.79 Of those women,
75.6% were registered patent attorneys and 24.4% were patent
agents.80 In contrast, 85.7% and 14.3% of the male patent practitioners

76. Work-Based Learning for World-Class Patent Examiners, U.S. DEP’T OF COM.,
https://www.commerce.gov/americanworker/work-based-learning-world-class-patentexaminers (last visited Jan. 1, 2022).
77. The federal courts have exclusive jurisdiction over cases “arising under” federal
patent law. See 28 U.S.C. § 1338(a). For a more detailed discussion of what, precisely, it means
for a case to arise under patent law, see Paul R. Gugliuzza, Rising Confusion About “Arising
Under” Jurisdiction in Patent Cases, 69 EMORY L.J. 459, 477–99 (2019).
78. Legal commentators have observed that the notion that careers in patent law are
only for those with backgrounds in the hard sciences is increasingly wrong. See generally Lee
Petherbridge & David L. Schwartz, The End of an Epithet? An Exploration of the Use of Legal
Scholarship in Intellectual Property Decisions, 50 HOUS. L. REV. 523, 552–53 (2012) (“Those who
teach patent law are aware that to this day there exist the remnants of a culture that preferred
attorneys with technical backgrounds to other attorneys . . . . Today that view seems
archaic . . . .”). Indeed, as one of us has shown in prior work, patent cases today are often
handled by the most prominent generalist litigators in the country, including well-known
appellate advocates such as Paul Clement, Carter Phillips, and Seth Waxman. Paul R.
Gugliuzza, The Supreme Court Bar at the Bar of Patents, 95 NOTRE DAME L. REV. 1233 (2020);
Paul R. Gugliuzza, Elite Patent Law, 104 IOWA L. REV. 2481 (2019).
79. Spector & Brand, supra note 56, at 2 fig. 4.
80. Id.
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were registered attorneys and agents, respectively.81 Though the
gender gap among practitioners at the USPTO remains wide, it is
closing. In 1950, there were almost no female patent agents or
attorneys, but that number has gradually increased, with the
biggest gains made in 1997 and 2011.82
Similar to what we see outside of law practice, although women
are generally poorly represented in most technological fields,
women are better represented in biotechnology and chemistry
patent prosecution.83 Specifically, women patent practitioners
represent 41.4% and 31.7% of the inventors seeking patents in the
biotechnology and chemical fields, respectively.84 These numbers
are in stark comparison to the lack of women representing
inventors seeking patents in computer science (14.8%), electrical
(11.4%), and mechanical (11.1%) fields.85
C. Women in Patent Litigation
Little empirical work has been done on the presence or absence
of women in patent litigation. The work that has been done
suggests that women are largely absent, at least when it comes to
work in the private sector. In a prior study, one of us (Gugliuzza)
showed that women argue far fewer patent cases at the U.S. Court
of Appeals for the Federal Circuit (which has exclusive jurisdiction
over all patent appeals nationwide)86 than their male counterparts,
with women arguing only 12.6% of cases from 2010 through 2019.87
Women were better represented in pharmaceutical patent litigation
at the Federal Circuit compared to other technology areas,
presenting 16.4% of arguments in those cases as compared to only
12.0% in non-pharmaceutical cases.88
Interestingly, gender inequality largely disappeared when the
analysis was limited to attorneys litigating patent cases on behalf of

81. Id.
82. Id. at 3 fig. 5.
83. Id. at 4 fig. 9.
84. Id.
85. Id.
86. 28 U.S.C. § 1295(a)(1). For more on the Federal Circuit’s jurisdiction, see Paul R.
Gugliuzza, Rethinking Federal Circuit Jurisdiction, 100 GEO. L.J. 1437, 1458–61 (2012).
87. Gugliuzza & Rebouché, supra note 15, at 1709 fig. 9.
88. Id. at 1726–27 figs. 20–21.
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the federal government.89 From 2010 through 2019, the USPTO
Office of the Solicitor was represented by women in about half of
the cases in which it presented oral argument at the Federal
Circuit.90 (The Office of the Solicitor serves as the USPTO’s legal
counsel on matters of intellectual property law.91 For the purpose
of this Article, the Solicitor’s Office’s most significant responsibility
is defending the USPTO’s decisions in patent examination or in
post-issuance review of patent validity when those decisions are
challenged in court.)92
Additionally, women make up almost a third of judges at the
PTAB—an important administrative tribunal within the USPTO.93
Moreover, five of the Federal Circuit’s twelve active judges are
women,94 and, among the court’s recent appointees, the women
tend to have more pre-appointment experience in patent law than
their male counterparts.
D. Requirements for Abbreviated New Drug Application
(ANDA) Litigation
Before discussing our empirical study of gender inequality in
pharmaceutical patent practice, some background on the unique
aspects of pharmaceutical patent litigation will be useful.
Branded pharmaceutical companies list patents covering their
products in the Food and Drug Administration’s (FDA’s) “Orange
Book.”95 A generic company that wishes to sell a product covered
89. Id. at 1713 fig. 13.
90. Id. at 1718–1719 figs. 18–19 (also showing that in 2013, 2014, and 2018 women
represented the majority of Federal Circuit oral arguments by the USPTO Solicitor’s Office).
91. See Office of the General Counsel, U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
about-us/organizational-offices/office-general-counsel (last visited Sept. 2, 2022).
92. See Office of the Solicitor, U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
about-us/organizational-offices/office-general-counsel/office-solicitor (last visited Sept. 2, 2022).
93. Amy Semet, A Data-Driven Analysis of the Patent Trial and Appeal Board’s First
Decade (unpublished manuscript) (on file with authors). The PTAB hears appeals from
rejections of patent applications and also conducts the new post-issuance proceedings
created by the America Invents Act, which began operation in 2012. See supra note 39.
94. Gugliuzza & Rebouché, supra note 15, at 1707 fig. 7.
95. The “Orange Book” (formally, the Approved Drug Products with Therapeutic Equivalence
Evaluations) is a list of drugs and pharmaceuticals that the FDA has approved as both safe and
effective. The Orange Book also includes the patent numbers associated with each product and
the calculated expiration dates of those patents. See Orange Book: Approved Drug Products with
Therapeutic Equivalence Evaluations, FDA, https://www.accessdata.fda.gov/scripts/cder/
ob/index.cfm (last visited Sept. 24, 2022).
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by a patent listed in the Orange Book has numerous options. Most
pertinent to this article, the relevant statutes provide incentives for
generic companies to challenge patents through what is called a
“paragraph IV” certification, under which the generic firm argues
that the branded firm’s Orange Book patents are either invalid or
not infringed by the generic product.96 In response to the paragraph
IV certification, the branded company may sue the generic
company for infringement.97
ANDA litigation—so named for the “abbreviated” new drug
application a generic company files with the FDA—is one of the
most complex types of litigation because it combines drug
regulatory practice with patent law, biology, and chemistry. Many
practitioners in this area have both a science degree and a law
degree. Additionally, many practitioners have a deep knowledge
of FDA law and procedure. However, the only formal requirement
to litigate in this area is the ability to practice in front of a federal
court, which usually requires only a law degree and admission to a
state bar.98
III. DATASETS AND METHODOLOGY
To examine gender representation in the important and highstakes area of pharmaceutical patent law practice, we built three
original datasets. The datasets contain demographic information
about (1) all patent examiners working at the USPTO who examined
all ANDA patents since 2005, (2) all lawyers who prosecuted ANDA
patents that were litigated to a final judgment on validity by
lawyers from a group of top law firms from 2009 through 2021, and
(3) all lawyers who litigated those same patents.
We built the first dataset using information obtained from a
Freedom of Information Act (FOIA) request filed with the USPTO.
To construct the second and third datasets, we compiled a list of
both litigated cases as well as litigated patents from 2009 through
2021. We examined all ANDA cases that were terminated from
96. 21 U.S.C. § 355(j)(2)(A)(vii)(IV). For a more complete description of the ANDA
litigation process, see Kenneth LAURENCE DORSNEY, ANDA LITIGATION: STRATEGIES AND
TACTICS FOR PHARMACEUTICAL PATENT LITIGATORS (3d ed. 2020); S. Sean Tu & Mark A.
Lemley, What Litigators Can Teach the Patent Office About Pharmaceutical Patents, 97 WASH. L.
REV. (forthcoming 2022).
97. 35 U.S.C. § 271(e).
98. See supra Section II.A.
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January 1, 2009 through December 31, 2021.99 To focus more closely
on cases that were actually litigated, we included in our analysis only
those cases that concluded with a final judgment based on the
validity provisions of the Patent Act: 35 U.S.C. §§ 101 (subject
matter or utility), 102 (novelty), 103 (nonobviousness), and 112
(written description, enablement, definiteness, and, prior to the
adoption of the American Invents Act, best mode).100 Our dataset
included 243 federal district court cases concerning a total of 379
patents. We further restricted the dataset to only those cases
involving the most active brand and generic lawyers, reducing the
number of cases to 169.101 Sixty of those cases (and 143 patents)
contained a finding of invalidity and 109 cases (and 236 patents)
contained a finding of no invalidity.
One limitation of our prosecutor and litigator datasets is that
they include only patents that were litigated to a final judgment by
lawyers from the most active law firms in the field. We chose to
focus on those patents because they represent some of the most
important patents for brand pharmaceutical firms—they are the
patents generic companies are willing to spend the full cost of
litigation on in an effort to invalidate. The patents litigated to a
final judgment are also contained within the cases that required
the most work by litigators because many of them went to trial.
99. During this time frame, there were 4,162 ANDA cases terminated. Most of those
cases (over half) were terminated due to express settlements between the parties, and
another 1,127 cases were terminated due to consent judgments, which are akin to settlements.
100. Out of the over 4,000 cases that were terminated from 2009 through 2021, 335 cases
ended in a judgment of some sort on either validity, infringement, or another issue. Out of
those 335 cases, in 243 cases, courts decided the validity of the patent. While a patent is
presumed valid, a court can find a patent invalid if a party proves by clear and convincing
evidence that one of the statutory sections of the Patent Act is not satisfied, as, for example,
if there was prior art that rendered the invention anticipated or obvious, if the subject matter
of the patent was not something that can be patented to begin with, or if certain requirements
regarding the write-up of the patent are not met. See generally Paul R. Gugliuzza, Patent
Law’s Deference Paradox, 106 MINN. L. REV. 1397, 1406–08 (2022), for more discussion of patent
law’s validity requirements. We used the database service LexMachina to compile our list of
cases. Cases coded by LexMachina as “ANDA” cases are included in the dataset. It is possible
that there may be some additional ANDA cases that were not coded by LexMachina as
ANDA cases. Also, by “final judgment,” we include cases coded by LexMachina as being
resolved in favor of the patentee or accused infringer on a motion for judgment on the
pleadings, a summary judgment motion, at a jury or bench trial, or through judgment as a
matter of law. At least half of the cases coded as being resolved in the patentee’s or claimant’s
favor were done so on consent judgements. These are not included in the analysis because
they are akin to settlements in most cases. See supra note 99.
101. See infra note 124 for a discussion of the law firms we included in our analysis.
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Because those litigated patents are important and sufficiently
valuable that both brand and generic companies would pay to
litigate them to judgment, it is crucial to understand who is
prosecuting those patents on the applicant side and who is
reviewing those patents on the examiner side.
A. Patent Examination
As explained above, there are two sides during patent
prosecution: (1) the USPTO patent examiner, who represents the
public interest, and (2) the inventor, represented by a patent
attorney or agent. We assembled a list of all patent examiners in the
biotechnology sciences and organic chemistry to assess the
representation of women as patent examiners. We then compiled a
separate list of the patent lawyers at top law firms who worked as
representatives of the inventors during the prosecution of patents
that were eventually litigated to a final decision on validity.
After determining the names of examiners, we coded them for
gender using the Social Security Administration’s list of top female
and male names for the years 1901–2000.102 Names on this list are
considered common and gender identifying, which accords with
methodologies previously used in the literature.103 For uncommon
or ambiguous names, we reviewed information such as law firm
websites and LinkedIn on each individual person to see how that
person identified their gender.104
As detailed in section III.A.1 below, in analyzing examiners,
we looked at all examiners who issued an ANDA-based patent
from 2005 through 2021, regardless of whether or not that patent
was later involved in litigation. As for the lawyers who
represented inventors during the prosecution process, we limited
the analysis to only those patents that were later resolved on

102. See Joshua Comenetz, Frequently Occurring Surnames in the 2010 Census, U.S. CENSUS
BUREAU (Oct. 2016), https://www2.census.gov/topics/genealogy/2010surnames/surnames.pdf.
A similar process was used to account for gender for patent prosecutors and litigators.
103. See, e.g., W. Michael Schuster, R. Evan Davis, Kourtenay Schley & Julie
Ravenscraft, An Empirical Study of Patent Grant Rates as a Function of Race and Gender, 57 AM.
BUS. L.J. 1 (2020).
104. We note that the male/female binary approach we have taken in this study does
not account for the myriad ways in which gender identity manifests. Though we are sensitive
to this issue, it bears emphasizing that this study often determined gender identity by
consulting biographical materials prepared by the practitioners themselves.
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validity grounds in federal court patent proceedings by lawyers
from top law firms.105
1. Pharmaceutical Patent Examiners
To assess gender representation on the USPTO side of
pharmaceutical patent prosecution, we obtained the names and
highest education levels for every patent examiner from 2005 to
2021 who worked in Technology Center 1600 from our FOIA
request. Technology Center 1600106 represents inventions that cover
“Biotechnology and Organic Chemistry,” and almost all Orange
Book patents come from it. 107 Unlike our prosecutor and litigation
datasets, which focused on patents that were eventually litigated
by lawyers from the most active firms in the field, this dataset is
broader and reflects all examiners who issued pharmaceutical
patents, even if they were never litigated in court.

105. Most challenges of patents are brought in the federal district courts. Patents can
also be challenged through an administrative process. As discussed supra note 39, any third
party can contest the validity of a patent through a proceeding at the PTAB. Challenges at
the PTAB are more limited than at the district court. For instance, inter partes review—the
most popular new proceeding—can only consider questions of novelty under § 102 and
nonobviousness under § 103 and can be based only on prior art references that are “patents”
or “printed publications.” 35 U.S.C. § 311(b). Patent validity can also be challenged through
proceedings at the International Trade Commission (ITC) when a party seeks an exclusion
order to prevent potentially infringing products from being imported into the United States.
See 19 U.S.C. § 1337; see also Sapna Kumar, The Other Patent Agency: Congressional Regulation
of the ITC, 61 FLA. L. REV. 529, 534 (2009) (providing an overview of patent proceedings at the
ITC). Though those other proceedings are important, our study focuses exclusively on
litigated patents that are challenged before the federal district courts because gender
inequality at the PTAB is already well-documented, see supra note 93, and because the small
number of patent proceedings filed at the ITC each year (between 50 and 100, give or take,
see Section 337 Statistics: Number of New, Completed, and Active Investigations by Fiscal Year
(Updated Quarterly), U.S. INT’L TRADE COMM’N (July 19, 2022), https://www.usitc.gov/
intellectual_property/337_statistics_number_new_completed_and_active.htm)) pales in
comparison to the roughly 4,000 patent cases filed in the district courts each year. DOCKET
NAVIGATOR, 2021 PATENT LITIGATION YEAR IN REVIEW 7 (2022), https://brochure.
docketnavigator.com/2021-year-in-review.
106. The USPTO’s corps of roughly 8,000 examiners is divided into nine “technology
centers,” which represent broad technology types, such as “biotechnology and organic
chemistry” and “computer networking.” Those technology centers are further divided into
“art units,” which represent narrower categories such as “immunology” and “cryptography
and security.” See Patent Technology Centers Management, U.S. PAT. & TRADEMARK OFF.,
https://www.uspto.gov/patent/contact-patents/patent-technology-centers-management.
107. Tu & Lemley, supra note 96, at 1678.
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This dataset includes 388 unique patent examiners.108 We coded
for gender (using the methodology described above), General
Schedule (GS) level,109 art unit (the specific type of art category
within the USPTO technology center),110 hire date, separation date,
and highest graduate degree. From the separation and hire date we
were able to calculate the average patent examiner tenure.111 For
those examiners who are currently working at the USPTO, we used
a separation date of December 31, 2021.112 We obtained most of this
information directly from the FOIA request; however, there was
information missing for about 15% of the examiners, so we looked
at LinkedIn, law firm websites, obituaries, and other online sources
to obtain the relevant information.113 When we were unable to find
the information online, we imputed the median value in
our analysis.114

108. Many examiners work in several art units within the same technology center.
Accordingly, we removed any duplicate examiners so that the dataset includes only
“unique” examiners.
109. The General Schedule (GS) pay scale is the federal government pay scale used to
determine the salaries of over 70% of federal civilian employees. See General Schedule (GS)
Payscale Table for 2021, FEDERALPAY https://www.federalpay.org/gs/2021 (last visited Sept.
24, 2022). Examiners typically start at GS-7, or -9 depending on education level and
experience and can advance through GS-15. There are ten steps within each GS grade. For
example, in 2021, GS-7 step 1 made an annual base salary of $43,683 while a GS-15 step 10
made $166,502. These salaries are also adjusted for localities and designed to reflect the
varying cost-of-living across different areas of the country. See id.
110. See supra note 106.
111. A few examiners left the agency and then rejoined it years later so their cumulative
tenure was calculated.
112. December 31, 2021 was chosen because that was the current date when coding
the information.
113. In addition, in a few cases, some of the data given by the USPTO in the FOIA
request was erroneous. For instance, an examiner might have a master’s, Ph.D., or law degree
that was not listed. It is also possible that some of the examiners may have obtained a law
degree or an advanced degree after departing the agency that was not accounted for in the
data. However, any degree obtained after an examiner’s tenure at the USPTO ended would
be irrelevant for the purpose of our study.
114. Failure to account for missing data could affect the analysis because it could be the
case that the missingness is correlated to some variable of interest. It is common in statistics
to impute the median value when there is missingness in the data. In this case, for the
roughly 15% of examiners for which we were missing information even after a thorough
online search, we assumed that they have an ANDA-based bachelor’s degree, and do not
have a master’s, Ph.D., or law degree.
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2. Pharmaceutical Patent Prosecutors for ANDA Litigated Patents
To assess who assisted inventors in prosecuting patents at the
USPTO, we isolated every patent from our dataset that was
litigated to a final judgment on validity by lawyers from select firms
and determined the names and registration numbers for the
“working” patent attorney or agent—that is, the prosecutor who
signed the majority of the Office Action responses. We obtained
these names from the patent prosecution history on the USPTO’s
Patent Application Information Retrieval (PAIR) system.115 We
reviewed each Office Action116 and recorded the working attorney
or agent who signed off on each Office Action response.
This dataset includes the 217 patent prosecutors who helped
inventors obtain every Orange Book patent that underwent litigation
in the district courts to a final validity decision from January 2009
through December 2021 by lawyers from select firms.117 Many patent
prosecutors were involved in multiple cases.118 We coded for
educational background (bachelor’s, master’s, doctorate, and law

115. See Check the Filing Status of Your Patent Application, U.S. PAT. & TRADEMARK OFF.,
https://www.uspto.gov/patents/apply/checking-application-status/check-filing-statusyour-patent-application (last visited Sept. 24, 2022).
116. An Office Action is written correspondence from the patent examiner to the
applicant stating grounds for rejecting the application. An Office Action requires a response
from the applicant to each ground of objection for prosecution of the application to continue.
Responding to Office Actions, U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
patents/maintain/responding-office-actions (last visited Sept. 24, 2022).
117. For a small number of prosecutors, where the Office Actions were unavailable, we
looked to the Attorney tab on PAIR, and if one clear attorney was listed, we included that
person. In most cases, we were not able to find any information about that person online, so
we could only ascribe a gender to them based on their name. We were not able to get
additional demographic information on fifty-three of the prosecutors, or about 25% of the
prosecutors involved in the litigated patents in our dataset. Of those fifty-three, we were not
able to get any information at all on thirty-one prosecutors (not even name or gender). This
is a significant limitation of our dataset, since it could be that the demographic profile of
prosecutors involved in litigation in the early years of the study particularly involving
patents issued before 2000 (whose file histories tend to be inaccessible online) may differ
systematically from patents issued in recent years. To the extent any data was missing, we
imputed the median value, which would be a male prosecutor, who attended law school,
and who majored in an ANDA-related science without an advanced scientific degree. Given
the time frame of the patents with unavailable prosecution histories, it is likely that most
prosecutors were male, so we doubt the missing information affects our results much.
118. While the median prosecutor was involved in two cases, 25% of prosecutors were
involved in prosecuting at least three litigated patents. The highest number of prosecuted
patents for a given prosecutor in the database was ten.
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degree),119 USPTO registration number, registration status (patent
agent or patent attorney), and date of registration as a patent
attorney and/or patent agent.120 We also determined if the
prosecutor was a registered patent agent or a registered patent
attorney (i.e., if they had a law degree).
B. Patent Litigation
There are thousands of litigators involved in ANDA litigation,
and many cases involve multiple firms representing different
parties. For example, it is not uncommon for both the brand name
pharmaceutical company and its licensee, if it has one, to be
separately represented. Moreover, multiple generic drug
companies may be attacking the validity of a single patent, with
each having its own lawyers and law firms. As such, to analyze the
demographic characteristics of all litigators involved in all ANDA
cases would be a monumental task. To make our dataset more
manageable, we limited our study to litigation involving only the
most active firms that litigated ANDA cases to a final judgment on
validity between January 1, 2009, and December 31, 2021.
In recent years, many law firms have formed practice groups
focusing on life sciences, ANDA litigation, and Federal Circuit
appellate litigation.121 This is especially true since most ANDA
litigation is geographically centralized in New Jersey and
Delaware.122 Moreover, the highest ranks of patent litigation is an
exclusive club: previous studies have shown that only a handful of
lawyers have presented a large proportion of Federal Circuit patent
arguments over the past decade.123 Accordingly, because much of
this type of litigation relies on repeat players, we chose to focus on
lawyers from the most active firms instead of doing a random
sample of all litigators. We defined active as the top five firms
119. As with information concerning examiners, educational and professional
information was recorded from various websites such as LinkedIn or more commonly a law
firm website with biographical information.
120. Registration information was obtained directly from the Office Action response.
Registration status and current city and state were obtained from the USPTO’s Office of
Enrollment and Discipline’s “find a patent practitioner” website. Find a Patent Practitioner,
U.S. PAT. & TRADEMARK OFF., https://oedci.uspto.gov/OEDCI/practitionerSearchEntry
(last visited Sept. 24, 2022).
121. Paul R. Gugliuzza, Pluralism on Appeal, 100 GEO. L.J. ONLINE 36, 42 (2012).
122. Tu & Lemley, supra note 96, at 1690.
123. Gugliuzza & Rebouché, supra note 15, at 1721–22.
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representing brand pharmaceutical companies and the top five
firms representing generic pharmaceutical companies, based on
number of ANDA cases litigated to a final judgment on validity
during the time period in question.124 We then determined the
names of the lawyers from each of the indicated firms.125 This
dataset includes 333 total litigators involved in 169 cases. Many of
these litigators are repeat players. The median litigator was
involved in five cases, with one litigator being involved in over
sixty cases.126
We then gathered additional information for each litigator,
including: (1) PTO registration number (if any), (2) gender, (3)
undergraduate major,127 (4) master’s degree, (5) Ph.D., and (6) law
school attended. The data was also segmented by whether the

124. The top five plaintiff’s firms representing brand pharmaceutical companies in
resolving disputes on the merits during the indicated time frame were: (1) Morris, Nichols,
Arsht & Tunnell; (2) Venable; (3) McCarter & English; (4) Finnegan, Henderson, Farabow,
Garrett & Dunner; and (5) Covington & Burling. The top five defense firms representing
generic pharmaceutical companies were: (1) Phillips, Goldman, McLaughlin & Hall; (2)
Winston & Strawn; (3) Young, Conaway, Stargatt & Taylor; (4) Richards, Layton & Finger;
and (5) Potter Anderson & Corroon.
125. To ensure that we did not include lawyers who were not active litigators, in order
to be included a lawyer must have litigated at least ten cases as of the termination date of the
case in question. As with the examination and prosecution data, if any data was missing, we
imputed the median value.
126. Each case can involve multiple patents that are resolved in different ways. In
patent litigation, parties challenge certain claims for validity, and the court may make its
determination about claims at different times. For example, the court could find on summary
judgment that some claims are not invalid, then later find at a bench trial that different claims
on that same patent are invalid. As such, each litigated case can have multiple outcomes if it
involves multiple patents. To simplify things for our empirical analysis, we came up with a
single measure of validity for each case. Many cases have a clear outcome with the court
holding all patents invalid or all not invalid. Where there was a split outcome and the case
involved multiple patents, we assigned the invalidity score to be based on the outcome for
the majority of the patents. If only one patent was involved, and there was a split verdict
among the claims, we assigned the case as invalid. Our analysis only considers the litigated
judgment, so if there were settlements or consent judgments among disputed patents, they
were not considered in the analysis to assign a validity value.
127. We were interested in whether the person had majored in an ANDA subject
matter. Thus, we also coded for “ANDA major” defined as a major in: Biology, Biochemistry,
Bioengineering, Bio-environmental Engineering, Biomedical Engineering, Biomedical
Science, Chemistry, Chemical Engineering, Polymer Science, Genetics, Immunology,
Molecular Biochemistry, Molecular Biology, Molecular Genetics, Microbiology,
Neuroscience, Toxicology, Pharmacy, and Veterinary Medicine. We were not able to obtain
undergraduate science major for many of the litigators as law firm websites and the like only
stated that the person had a bachelor of science degree. To the extent such information was
not available, we assumed that the person did not have an ANDA-related degree.
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lawyer represented the brand or generic pharmaceutical company
and if the patents were ultimately found invalid or not invalid.128
C. Limitations
To be clear, our analysis does not cover a representative sample
of all ANDA prosecutors nor even all ANDA prosecutors who have
their patents later litigated in court. It is also not representative of
all ANDA litigators. Rather, our analysis is narrowly tailored only
to prosecutors who later have their patents litigated to a final
validity conclusion by a lawyer from one of the most active law
firms in ANDA litigation. There are roughly 4,000 patent
infringement suits filed in the United States every year involving
tens of thousands of patents.129 It would be a monumental
undertaking to analyze the demographic profile of every
prosecutor or litigator of every patent asserted in ANDA litigation.
Our analysis thus focuses solely on patents litigated by the law
firms that appear most frequently in the district courts and on the
patents that reach a final judicial decision on validity. We think this
is a critical subset of cases and lawyers because they represent the
most hotly contested and highest-stakes pharmaceutical patent
disputes and thus provide important insight into what the upperechelon of pharmaceutical patent practice looks like.
It could be that these firms are not representative of law firms
in general or patent firms in particular. Because the law firms in our
dataset tend to be large, they may differ in their propensity to only
have senior partners sign Office Action responses or appear on
court filings. Junior lawyers may work on matters, yet not have
their name attached, and as such they would not be included in our
data. Still, the point of our study is to assess gender equality (or the
lack thereof) at the highest levels of patent law practice, so, to the
extent women are working on these matters but do not have their
names associated with them, that would actually prove our point.
128. This dataset includes only ANDA litigated patents. Accordingly, plaintiffs’
lawyers are defined as a brand pharmaceutical company who brought an ANDA
infringement case against a generic drug company under 35 U.S.C. § 271(e)(2). Defense
lawyers were defined as generic companies who most often bring paragraph IV challenges
in an attempt to argue non-infringement or to invalidate the brand company’s patents. See
supra Section II.D.
129. See Gene Quinn, Patent Litigation in the United States, 1980 to 2020, IPWATCHDOG
(Nov. 4, 2021), https://www.ipwatchdog.com/2021/11/04/patent-litigation-in-the-unitedstates-1980-to-2020/id=139510.

167

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

12/10/22 7:14 PM

BRIGHAM YOUNG UNIVERSITY LAW REVIEW

48:1 (2022)

Our study does not nor was it designed to offer insights into
disparities for all ANDA-related patent litigation. Although we
would hypothesize that there is some disparity—and our data
suggests that there is, in fact, substantial disparity—how wide or
narrow that disparity is in other ANDA-related litigation is not
something our study was designed to test.
Another limitation is that litigators at smaller law firms do not
appear in our data. It could be that they differ from the big firms
where gender inequality is long-standing and well-documented.130
Also, since we determined the top firms based on whether their
cases were litigated to a final judgment, our analysis necessarily
would exclude firms where settlement is popular. It could be, for
example, that a law firm that settles more often differs in its
demographics. Again, however, cases that end in settlement are
less relevant to our research interest into gender inequality at the
highest levels of patent practice. Cases with high settlement rates—
such as the low-value cases brought en masse by so-called patent
trolls—are not considered the most elite field of patent
law practice.131
Mindful of these limitations, we believe our datasets capture
crucial insights about the demographics of pharmaceutical patent
law practice. The patents covered by our dataset—which were
ultimately litigated to a final judgment by the most active patent
law firms in the country—are some of the most important patents
to both brand and generic pharmaceutical firms, as evidenced by
the fact that both sides were unwilling to settle and required a final
court ruling. Additionally, the litigations captured in our dataset
are among the most labor intensive and include many hours
associated with discovery, motions, trial, and appeal. These
litigations require litigators to engage in complex litigation
strategy, motion practice, brief writing, and oral advocacy.
Accordingly, the sample of litigations and patents covered by our
dataset represent some of the most high-stakes cases and valuable
intellectual property rights that exist. These are precisely the types
130. See supra Section I.C.
131. See David L. Schwartz, The Rise of Contingent Fee Representation in Patent Litigation,
64 ALA. L. REV. 335, 369–70 (2012) (“At the ‘bottom’ of the patent contingent market are very
small patent contingent firms. . . . The patents are enforced against an entire industry, or
alternatively against a slew of defendants in a single lawsuit. They litigate these cases very
sparingly, attempting to avoid motion practice and substantial discovery.”).
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of high-level matters on which we might be most concerned to find
significant gender disparities.132
1. Patent Prosecution
There are a few additional limitations specific to how we
analyzed prosecutors. First, our dataset focused on patents that had
a prosecution history that was available on public PAIR. Electronic
copies of the patent prosecution histories are generally only
available for patents with a filing date from 2000 to present.
Accordingly, most patents that were filed before 2000 were not
included in our dataset,133 but we do not believe this limitation
affects our results much.134
A second limitation for patent prosecution coding, which we
alluded to above, is that the person who signs off on the Office
Action response may not always be the “working” attorney or
agent. Specifically, junior associates may write the Office Action
response, but the senior partner may review and sign the response.
Unfortunately, our study cannot capture these events simply
because if the “working” associate does not sign the response,
there is no way of knowing who did the majority of the work.
Accordingly, while there may be an undercount of female
involvement in prosecution work, we assume that the most
involved practitioner was the one who “signed” the Office
Action response.135

132. For analyses of gender inequality at the highest levels of corporate work more
generally, see Naomi Cahn, June Carbone & Nancy Levit, Discrimination by Design, 51 ARIZ.
ST. L.J. 1, 7 (2019); June Carbone, Naomi Cahn, & Nancy Levit, Women, Rule-Breaking, and the
Triple Bind, 87 GEO. WASH. L. REV. 1105, 1109 (2019).
133. There may be other prosecutors for patents that were filed after 2000 that were not
included because there was not a file history noted in PAIR. For any patents missing
prosecutors, we also looked at the “Attorney Information” tab on PAIR to see if we could
gain additional information about the fifty or so patents that were missing matching
prosecutor information. In most cases, only a law firm or the pharmaceutical company’s
in-house legal team was listed, thus preventing us from obtaining further information on
which lawyer prosecuted the patent.
134. See supra note 117.
135. In ten cases, two lawyers were listed on the signature block of the Office Action
response. To gauge which lawyer should be included in the database, we looked at which of
the two (or in one case three) actually signed the Office Action, even if they signed for
someone else. Where there was still a discrepancy, we reviewed multiple Office Actions if
they were available to come up with the lawyer who seemed to be most involved during the
prosecution of the patent.
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2. Patent Litigation
Similar to the patent prosecution dataset, if a litigator does not
enter an appearance or sign a legal brief, then they will not be
captured by our dataset. Thus, if any litigator did work but was not
recorded on any Public Access to Court Electronic Records (PACER)
document, then they are unaccounted for in our dataset.136 This
could be a limitation since there may be a wide disparity among law
firms in whether junior (and more female) attorneys are recorded
in PACER as being a part of the case. But, again, if women are being
undercounted in this fashion, that reinforces our point—women
are disproportionately unrepresented at the highest levels of
pharmaceutical patent litigation practice.
To be clear, we do not intend and cannot make conclusions
about whether there is gender disparity among all patent litigators
for all ANDA litigation pending before the federal courts. Many
ANDA cases do not involve lawyers from one of the ten firms we
studied.137 Rather, our analysis focuses on the more targeted issue
of whether there is gender disparity concerning the litigation of
patent cases to a conclusion by lawyers coming from the busiest
ANDA litigation law firms.
IV. RESULTS
To recap: our study focuses on gender inequality in the
pharmaceutical patenting area. Our data is segmented into patent
prosecution and patent litigation, with patent prosecution data
further segmented into patent examiners and patent prosecutors.
The patent examiner data includes all patent examiners from the
USPTO’s Technology Center 1600, the administrative unit within
the USPTO from which most pharmaceutical patents issue.138
The patent prosecutor and patent litigator data focus only on those
patents that were litigated to a final judgment on validity by the

136. In addition, our analysis is necessarily limited by the information that LexMachina
captures from PACER, so if there was an error here and there then the lawyer would not be
accounted for.
137. All told, our database involving the ten most litigated brand and generic
pharmaceutical companies accounts for about two-thirds (68%) of terminated ANDA cases
during the time frame under study that was litigated to a final judgment involving validity.
The remaining third of litigation do not involve the ten law firms involved in our study.
138. See supra note 106.
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most active firms in the field. Finally, the patent litigators are
subdivided into plaintiffs’ lawyers (i.e., generally lawyers
representing branded companies) and defendants’ lawyers (i.e.,
generally lawyers representing generic companies). We also coded
for whether the relevant patents were found invalid or not invalid.
A. Pharmaceutical Patent Prosecution
There are two sides to patent prosecution. First, there are patent
agents and attorneys who help inventors obtain patents for their
invention. Second, there are the patent examiners who represent
the USPTO and ensure that applications meet the relevant
patentability requirements. We examine gender representation on
each side.
1. Pharmaceutical Patent Examiners
Figure 3 shows the gender makeup for the 388 pharmaceutical
patent examiners in Technology Center 1600 at the USPTO
employed from 2005 through 2021. As will become clear shortly,
the gender makeup of the USPTO examiner corps is surprisingly
balanced when compared to the prosecutors who practice before
it.139 Women represent 42.3% of the patent examiners in our dataset
and men represent 57.7%.

139. See infra Section IV.A.2.

171

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

12/10/22 7:14 PM

BRIGHAM YOUNG UNIVERSITY LAW REVIEW

48:1 (2022)

0

.2

Percent
.4

.6

.8

Figure 3: Patent Examiner Percentages, by Gender

Gender
Male

Female

Table 1 and Figure 4 below show that the patent examiners in
our dataset do not vary by gender in terms of educational
backgrounds, average promotional level, and experience at the
USPTO. Women are near equal to men in their proclivity to have
an educational background in an ANDA field; 95.1% of women
have ANDA backgrounds compared to 93.3% of men. There are
also approximately the same number of women and men who have
either a master’s degree or a doctorate in an ANDA-related field.140
Although slightly more men (76.9%) than women (73.2%) have an
advanced science degree in an ANDA field, these differences are
not statistically significant.141 There is also not a gender disparity
with respect to whether patent examiners have a law degree, at
140. Data was gathered on the entire relevant population. To illuminate the data
further, analysis was done using chi-squared tests, which measure the likelihood that the
observed difference between the genders’ frequencies is due simply to chance. The standard
confidence level of 95% is used unless otherwise stated. In other words, if a result is
significant at the p=0.05 level, there is a 5% chance of an incorrect inference.
141. By contrast, men have higher rates of obtaining a doctorate in an ANDA-related
field, a difference that is statistically significant. This pattern is the same regardless of
whether or not the advanced degree is in an ANDA-field. The majority of examiners with
advanced degrees have an advanced science degree in an ANDA-related field. For many
doctoral programs, if a student enters into the Ph.D. program but fails the qualification
examination, he or she usually exits with a master’s degree.
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least measured as of the time they were working at the USPTO and
thus accounted for in our data.142
Not only are patent examiner educational levels approximately
the same, but the tenure and pay grades are also very similar,
regardless of gender. Although the difference in the doctorate rate
between females and males is statistically significant, such
disparity is less relevant for patent examiners because the tenure
and pay grades are also very similar regardless of gender. Table 1
shows that the highest promotional level, as measured by General
Schedule (GS) level,143 and the length of time on the job are
approximately the same for both women and men. Indeed, women
measure slightly higher on both metrics.
Table 1: Patent Examiner Education/Professional Background
Percentages, by Gender
ANDA

Master’s

Ph.D.

Advanced

J.D.

Average
GS144

Male
93.3
22.8
55.4***
76.9
10.3
11.9
Female
95.1
28.7
44.5***
73.2
11.6
12.0
* 90% confidence, ** 95% confidence, *** 99% confidence. N=388.

Average
Tenure
(days)
2993
3183

Figure 4: Patent Examiner Percentages, by Gender and
142. The information we obtained from the USPTO allows us to only assess whether an
examiner had a law degree as of the date they were employed by the agency. A cursory look
at the profiles of some of the examiners after leaving the agency reveals that many examiners
subsequently obtained law degrees after leaving the agency. These later-obtained law
degrees are not reflected in our data, which is appropriate because this study focuses only
on examiner education at the time examiners were employed at the USPTO (and not the
education that the examiner may have received after the examiner left the USPTO).
143. See supra note 109.
144. Some people had left the agency and came back or were reflected multiple times
in the data when they changed GS levels. The highest GS level was used for this analysis.
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Overall, our data suggest that, with government jobs in the
patent prosecution field, there seems to be general equality
between the genders in qualifications, hiring, tenure, and pay.
Specifically, many examiners have a degree in an ANDA-related
science. Those with equal educational backgrounds are treated
similarly when it comes to tenure and pay. In contrast, as we show
below, there is a large gender disparity in private practice.145
2. Pharmaceutical Patent Prosecutors
Unlike with examiners at the USPTO, there is a much larger
gender disparity when it comes to private practice that applies to
both prosecutors and, as we show in section IV.B, litigators.146
Figure 5 shows that, of the 217 patent prosecutors in our dataset
from the most active firms who worked on litigated pharmaceutical
patents that terminated in a final judgment on validity, 75.1% are
men and only 24.9% are women, a nearly fifty-percentage-point

145. See infra Section IV.A.2.
146. See infra Section IV.B.
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disparity that is far disproportionate to the share of women in the
legal profession and in American law schools.147
Figure 5: Patent Prosecutor Percentages, by Gender
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Crucially, Table 2 and Figure 6 below show that the education

Gender
Male

Female

levels of women in patent prosecution are similar to those of men,
refuting the notion that a pipeline problem is impeding women’s
participation in patent prosecution. The women and men in our
dataset have similar backgrounds in ANDA-related training, with
59.3% of women having an ANDA-based degree compared to
58.3% of men. Similarly, women have advanced degrees in a near
equal proportion to men (35.2% versus 35.0%). Further, while men
have more master’s degrees (16.0% versus 14.8%), a larger
percentage of women (24.1%) than men (22.1%) have doctorates,
although neither difference is statistically significant.
Additionally, regardless of gender, most of these patent
prosecutors are patent attorneys, not patent agents. While women
147. See supra Section I.B. Most of the demographic information, such as educational
and professional information, was compiled using only the names of the 186 prosecutors for
which we could obtain a name. Statistics were computed based on the 217 prosecutors by
imputing the median to those with missing values.
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are slightly more likely to be agents, the difference is only
significant at 90% confidence. Specifically, 96.9% of men and 90.7%
of women prosecutors are also registered patent attorneys.148 This
high rate of prosecutor-lawyers is consistent with previous studies
that have shown that 76% of women and 86% of male prosecutors
are registered patent attorneys.149
All in all, the data show that women and men have virtually
indistinguishable educational and professional backgrounds,
making the near fifty-percentage point discrepancy in their overall
representation among the patent prosecution bar perplexing.
Table 2: Patent Prosecutor Percentages, by Gender and
Educational/Professional Background
ANDA
Master’s
Ph.D.
Advanced
Male
58.3
16.0
22.1
35.0
Female
59.3
14.8
24.1
35.2
* 90% confidence, ** 95% confidence, *** 99% confidence. N= 217.

J.D.
96.9
90.7

Agent-Only
3.1*
9.3*

148. The few patent prosecutors who were not coded as going to law school have very
low registration numbers (representing that they passed the patent bar before 1970). For
many of these patent prosecutors, we were unable to determine if they attended law school
because they have long retired and do not have websites describing their educational
background. In more recent times, there are some patent prosecutors who worked as patent
agents at law firms.
149. All of the prosecutors have USPTO registration numbers. This is not surprising
because to prosecute patents in front of the USPTO requires licensure by the USPTO. Spector
& Brand, supra note 56, at 4 fig. 4, shows that 21.8% of all USPTO registered attorneys and
agents are women. 75.6% of those women are patent attorneys and 24.4% are agents. Men
make up 78.2% of all USPTO registered attorneys and agents. 85.7% of those men are
registered as attorneys and 14.3% are registered as agents.

176

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

177

12/10/22 7:14 PM

Overqualified and Underrepresented

0

.2

.4

Percent
.6

.8

1

Figure 6: Patent Prosecutor Percentages, by Gender and
Educational/Professional Background

Male
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Gender
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Interestingly, however, women prosecutors are more likely
than men to have their patents invalidated in court. Women have
their patents invalidated 50.5% of the time, while only 32.7% of
patents prosecuted by men are invalidated, a difference that is
statistically significant at the 95% confidence level. Of course,
there are many factors that impact whether or not a patent is
declared invalid, such as the complexity of the patent, the
wordiness of the claims, and the date of the patent, among
others.150 The gender disparity we document does not control for
any of those factors so, while it is interesting to note, we cannot claim
it has any causal significance.
B. Pharmaceutical Patent Litigation
Similar to patent prosecutors working in private practice,
there is a large gender disparity among patent litigators in private
practice. Figure 7 below shows that, of the 333 patent lawyers who
litigated pharmaceutical patents in our dataset, 62.5% are men and
150. See Colleen V. Chien, Predicting Patent Litigation, 90 TEX. L. REV. 283, 287 (2011).
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only 37.5% are women. This nearly 30% gender disparity is not as
large as it is among prosecutors, but it still is disproportionate to
the share of female lawyers overall and the share of female law
students with scientific backgrounds. These data are also consistent
with prior articles showing that, while women are largely absent
from patent litigation across all areas of technology, there is greater
representation of women when it comes to litigation in the
pharmaceutical industry.151 One of us, for example, has shown that
the litigants who had more than 20% of their Federal Circuit oral
arguments presented by female attorneys were disproportionately
companies in the pharmaceutical industry.152
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Figure 7: Patent Litigator Percentages, by Gender

Gender
Male

Female

Table 3 below shows that the education and experience levels of
women in patent litigation is similar to that of men, again refuting

151. Gugliuzza & Rebouché, supra note 15, at 1726 fig. 20 (16.4% of Federal Circuit
arguments were presented by women in pharmaceutical cases as compared to 12.0% in nonpharmaceutical cases).
152. Id. at 1724 tbl. 1 (showing that Mylan, Apotex, Watson, and Sandoz all had a
greater than 20% of their arguments presented by women attorneys).
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the pipeline argument in the pharmaceutical field. Although not
statistically significant, as shown in Table 3 and Figure 8, the women
patent litigators in our dataset tend to have higher education levels
than the male litigators in our dataset. Specifically, women have a
higher percentage of bachelor’s, master’s, and doctorate degrees.153
Fewer female litigators, however, are members of the patent bar
(38.4% versus 42.3%), but that difference is not statistically significant.
These data contradict the idea that litigators need to be
admitted to the patent bar or need science degrees to litigate
patents. Overall, according to our database, only 61.3% of ANDA
litigators have bachelor of science degrees, 48.1% have degrees in
ANDA-related fields,154 and 40.8% are registered patent
attorneys.155 Yet, though the differences are not statistically
significant, women litigators in our dataset actually score higher in
science degrees (64.0% versus 59.6%), ANDA-related degrees
(55.2% versus 46.6%), master’s degrees (12.0% versus 10.6%), and
doctorates (13.6% versus 10.1%).
Table 3: Patent Litigator Percentages, by Gender and
Educational/Professional Background
B.S.156
ANDA
Master’s
Ph.D.
Male
59.6
46.6
10.6
10.1
Female
64.0
55.2
12.0
13.6
* 90% confidence, ** 95% confidence, *** 99% confidence.

Advanced
17.8
23.2

Registered
42.3
38.4

153. These figures are reported by each individual person, with each person in the
database as a unique observation.
154. The list of ANDA degrees are defined in supra note 127.
155. These numbers are derived from our dataset of cases litigated to a judgment on
the validity of a patent and involving large law firms. Where data is missing, we made some
assumptions about whether or not someone has a science or ANDA-based degree. Many
lawyers simply list that they have a bachelor of arts or bachelor of science degree, without
indicating their specific major. Where the major was not listed, we assumed it was in a nonANDA-related topic. This may undercount the true number of ANDA-majors, but we have
no reason to believe that this undercount would disproportionately affect women versus
men. Further, if a lawyer’s information simply stated he or she had a bachelor’s degree, we
assumed he or she did not have a science degree. This was not always true, as some colleges
(particularly liberal arts colleges) only award bachelor of arts degrees, yet students still major
in fields such as chemistry or biology. Again, to the extent this assumption was wrong, we
have no reason to believe it disproportionately affects women over men or vice versa.
156. This represents a bachelor of science, regardless of whether it is in an
ANDA-related field.
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Figure 8: Patent Litigator Percentages, by Gender and
Educational/Professional Background
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Table 4 and Figure 9 below look at case-lawyer-gender pairs as
the unit of analysis to discern whether the male-female ratio
changes when the data is segmented by brand or generic lawyers
or when segmented by invalid or not invalid judgments.157 To be
sure, use of the case-lawyer-gender pair may overstate some law
firms and lawyers in the database. For example, firms representing
branded pharmaceutical companies (such as Finnegan and
Covington & Burling) often have large teams working on their
cases, while many of the law firms representing generic companies
have smaller teams. Moreover, there are more repeat players
especially among the law firms representing generic companies,
with the same lawyers representing generics over and over again.
Still, as shown on Table 4 and Figure 9, there is a statistically
significant difference at the 95% confidence level concerning
gender differences with respect to representation of brands versus
generics. Females disproportionately represent generic companies
157. In total, there are 1,402 observations of case-lawyer-gender pair, with no
duplicates removed. The ratios are approximately the same when the analysis includes
unique names only.
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(34.8%) compared to brands (27.4%), while men have a higher rate
of representing brands (72.6%) versus generics (65.2%). This
suggests that there is a greater proportion of women at some of the
smaller firms that generally represent generics than at the largest,
most prestigious firms that tend to represent branded companies—
further evidence of the acute absence of women at the highest levels
of private law practice.
Table 4: Patent Litigator Percentages, by Gender, and Whether
Represent Brand/Generic Pharmaceutical Company, and
Validity Outcome
Brand

Generic

Overall
Male
Female

72.6**
27.4**

65.2**
34.8**

Invalid
Male
Female

73.3
26.7

71.8
28.2

Not Invalid
Male
72.3***
Female
27.7***
* 90% confidence, ** 95% confidence, *** 99% confidence.

61.9***
38.1***
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Figure 9: Patent Litigator Percentages, by Gender, and Whether
Represent Brand/Generic Pharmaceutical Company

Brand
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Gender
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C. Education and Pharmaceutical Patent Litigation
Table 5 and Figure 10 below break down the data by the
educational qualifications of the 333 lawyer-gender pairs by type of
litigant. For example, as shown in Figure 10, it is apparent that
lawyers representing generics have lower educational
qualifications, in terms of degrees. Overall, lawyers representing
generic pharmaceutical companies have a lower percentage of
science or advanced degrees as well as represent a lower
percentage of USPTO registered patent attorneys compared to
lawyers representing brand pharmaceutical companies, a
difference that is statistically significant at 99% confidence.
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Table 5: Patent Litigator Percentages, by Gender,
Educational/Professional Background, and Whether Represent
Brand/Generic Pharmaceutical Company
B.S.

ANDA

Master’s

Ph.D.

Advanced

Registered

Overall158
Brand
Generic

75.9***
34.2***

62.0***
27.4***

13.4*
6.8*

16.2***
2.6***

25.5***
9.4***

49.5***
24.8***

Brand: Overall
Male
Female

73.5
80.0

56.6**
71.3**

13.2
13.8

13.2
21.3

22.1
31.3

50.0
48.8

Generic: Overall
Male
33.3
27.8
5.6
4.2
Female
35.6
26.7
8.9
0.0
* 90% confidence, ** 95% confidence, *** 99% confidence.

9.7
8.9

27.8
20.0
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Figure 10: Patent Litigator Percentages, by Gender,
Educational/Professional Background, and Whether Represent
Brand/Generic Pharmaceutical Company
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158. These figures are generally the same if the data is further broken down by whether
the patent in the case-lawyer-gender pair is ruled invalid or not invalid. This data reinforces
the fact that brand pharmaceutical companies are generally represented by lawyers with
greater education.
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Further, women who represent brands typically have higher
levels of education than men who do. Limited to lawyers
representing brand pharmaceutical companies, female lawyers
disproportionately have an ANDA-related degree (71.3%) compared
to men (56.6%), a difference that is statistically significant at the 95%
confidence level. There are virtually no differences between the
genders for lawyers representing generics. In fact, the data show
that most litigators for generic pharmaceutical companies do not
have a science degree. In contrast, Table 5 and Figure 10 show that
the most scientifically educated patent litigators represent the
brand companies. Yet, despite the fact that female litigators are
better educated than men, men still are disproportionately
represented at firms representing brand companies. This finding of
women appearing to have superior qualifications accords with
literature suggesting that, to succeed in high-stakes corporate
environments, women are disproportionately required to “prove
themselves over and over again.”159
Table 6 below compares how diverse teams fare with respect to
validity outcomes. About 81.1% of cases involved at least one
female litigator. In order to determine whether a team was diverse,
we calculated the ratio of female lawyers to total lawyers on the
case. The median was 0.29, meaning that over half of the teams in
ANDA cases have less than a third of the lawyers on the team who
are female. We then constructed a dichotomous variable with “1”
indicating that the litigation team has a higher female-to-male
membership ratio than the median litigation team in our dataset.160
With a dichotomous variable, we could then compare invalidation
rates based on whether or not the team was diverse.
We similarly constructed a dichotomous measure based on
advanced degrees, with a value of “1” for groups that had above
the mean value of 14.5% for an advanced degree. This gave us a
way to measure whether more educated teams (defined by having

159. See, e.g., Joan C. Williams, The Five Biases Pushing Women Out of STEM, HARV. BUS.
REV. (Mar. 24, 2015), https://hbr.org/2015/03/the-5-biases-pushing-women-out-of-stem.
160. These ratios are of course approximate. Moreover, we only selected lawyers from
the most active law firms, so it could be the case that a lawsuit involving many different
firms have a different ratio than what we assign to each case. Nonetheless, we think that the
ratio of female lawyers to total lawyers at the large firms gives at least some measure of how
diverse the team representing the client was.
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an advanced degree) have different outcomes on validity to a
statistically significant degree.
Table 6 below presents the data based on the two dichotomous
variables regarding team diversity and education, comparing
invalidation rates between brands and generics. Invalidation rates
do not markedly differ based on whether the team is more diverse
or more educated. Though not significant (barely), diverse teams
with more women have lower rates of invalidation, a “winning”
outcome for the brand pharmaceutical companies. With respect to
education, teams composed of those with more than the mean for an
advanced degree fare no better or worse with respect to outcomes.
Table 6: Patent Litigation Outcome Percentages, Whether
Diverse/Not Diverse, and Whether More Educated/Less Educated
Overall
Invalid
Not Invalid
Brand
Invalid
Not Invalid
Generic
Invalid
Not Invalid

Diverse

Not Diverse

Educ

Less Educ

31.0
69.0

40.2
59.8

34.8
65.2

36.3
63.8

29.3
70.7

38.5
61.5

33.3
66.7

25.8
74.2

32.6
67.4

43.3
56.7

37.9
62.1

42.9
57.1

* 90% confidence, ** 95% confidence, *** 99% confidence.

V. TOWARDS WOMEN’S INCLUSION IN PATENT LAW
This study expands the scope of previous studies161 and finds
that women rarely litigate pharmaceutical patents for private sector
clients in the federal district courts. Additionally, women do not
prosecute pharmaceutical patents for private sector clients at rates
comparable to their male counterparts.
These data are particularly interesting because, unlike in many
areas of science, women are well-represented in biological,
chemistry, and health care related fields.162 Additionally, women
161. E.g., Gugliuzza & Rebouché, supra note 15.
162. See OFF. OF THE CHIEF ECONOMIST, U.S. PAT. & TRADEMARK OFF., PROGRESS AND
POTENTIAL: 2020 UPDATE ON U.S. WOMEN INVENTOR-PATENTEES 7 (2020),
https://www.uspto.gov/ip-policy/economic-research/publications/reports/progresspotential [hereinafter 2020 UPDATE].
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who have science backgrounds are equally represented among
students attending law school. Our data thus call into question the
idea that simply increasing the number of women in the sciences
will bring about gender equality in the pharmaceutical field. There
already are a lot of women in pharmaceutical-related scientific fields,
but they do not make it to the highest levels of pharmaceutical
patent law practice.
Interestingly, this gender disparity is not found in many
government jobs related to patent law. Specifically, patent
examiners working at the USPTO within the pharmaceutical art
units see something close to gender parity.163 This finding is
consistent with prior scholarship observing proportionately greater
gender equality in patent-related jobs in the public sector, whether
as PTAB judges, Federal Circuit judges, or lawyers at the USPTO
Solicitor’s Office.164
Patent litigation and patent prosecution in the pharmaceutical
sector are two of the most lucrative areas of practice.165 Obtaining
patents in the pharmaceutical sector can represent billions of
dollars of revenue for pharmaceutical firms and millions of dollars
in revenue for the law firms that represent them.166 Also similar to
other lucrative and prestigious areas of law, women are
underrepresented.167 This is most likely because most law firm
partners are male and—consciously or not—resist surrendering
control over these high-value clients. To incentivize greater gender
parity, firms could begin to tie compensation directly to diversity
and inclusion goals.168 Shy of that, however, reform will likely have
to come outside of the law firm community.

163. See supra Section IV.A.1.
164. See Gugliuzza & Rebouché, supra note 15, at 1713 fig. 13; Semet, supra note 93.
165. See generally Most Lucrative Areas of Law 2021: Top 7, BSCHOLARLY,
https://bscholarly.com/most-lucrative-areas-of-law (listing intellectual property law among
the highest paying areas of law) (last visited Oct. 15, 2021).
166. See Chandra Mohan, S.B. Puranik, Prasanna Sagar, Swamy Sreenivasa & Madhu
Rao, Patents—An Important Tool for Pharmaceutical Industry, 2 RES. & REV.: J. PHARM. &
NANOTECHNOLOGY 12 (2014).
167. See, e.g., Afra Afsharipous, Women and M&A, 12 UC IRVINE L. REV. (forthcoming
2022) (showing that women are underrepresented in mergers and acquisitions transactions).
168. See, e.g., Iain Carlos, DEI Is Now a Factor in Executive Pay. But There’s One Big
Disconnect, BUS. J. (July 29, 2021), https://www.bizjournals.com/bizjournals/news/
2021/07/29/dei-is-not-in-long-term-incentive-programs.html.

186

3.GUGLIUZZA.FIN.NH.DOCX (DO NOT DELETE)

187

12/10/22 7:14 PM

Overqualified and Underrepresented

In this final Part of the Article, we sketch ways in which
Congress and the USPTO could further gender equality in patent
law practice, discuss steps law firms and their clients could take to
the same end, and assess whether some steps the USPTO has
recently taken have succeeded in nudging patent practice toward
gender parity.
A. Congressional and USPTO Solutions
Both Congress and the USPTO are aware of the lack of gender
and racial diversity in the patent bar and are exploring several
approaches to address the issue. Over the past few years, both the
House and Senate have held hearings on so-called “lost Einsteins”
who are not included in the patent law system.169 The USPTO
recently took on the charge of creating a new database linking up
historical data to code each patent with the inventor’s gender to
spur research in the field.170
Congress is currently considering the Unleashing American
Innovators Act to address the diversity gap.171 This Act would
establish additional USPTO satellite offices in locations where there
are underrepresented demographic groups. These offices will
target the Southeastern region172 of the United States to “increase
participation in the patent system by women, people of color,
veterans, individual inventors, [and] members of any other
demographic, geographic, or economic group that . . . [is]
underrepresented in patent filings.”173 Furthermore, the Act
attempts to bolster the patent pro bono program174 and create a preprosecution patentability assessment program.175 Each of these
programs endeavor to help low-income inventors in disadvantaged
169. See, e.g., House Judiciary Committee, Lost Einsteins: Lack of Diversity in Patent
Inventorship and the Impact on America’s Innovation Economy (Mar. 27, 2019),
https://judiciary.house.gov/calendar/eventsingle.aspx?EventID=1802;
House
Small
Business Committee, Enhancing Patent Diversity for America’s Inventors (Jan. 15, 2020),
https://www.congress.gov/event/116th-congress/house-event/LC65529/text?s=1&r=24.
170. See 2020 UPDATE, supra note 162.
171. Unleashing American Innovators Act of 2021, S.B. 2773, 117th Cong.
172. The Southeastern region of the United States is defined as Virginia, North
Carolina, South Carolina, Georgia, Florida, Tennessee, Alabama, Mississippi, Louisiana, and
Arkansas. Id. § 2(4).
173. Id. § 3(c)(2).
174. Id. § 5.
175. Id. § 6.
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geographic locations gain better access and help them understand
the patent system.
The USPTO has also responded to a lack of diversity by
changing the requirements for admission to the patent bar. In 2021,
the USPTO changed the “technical and scientific qualifications”
necessary to take the patent bar exam.176 These changes expanded
eligibility for the patent bar exam to a wider range of degrees and
were made, in part, as a response to the low gender diversity in the
patent bar.177
Specifically, the USPTO made three changes to the patent bar
eligibility requirements: (1) expanding the list of “Category A”
bachelor’s degrees that are accepted as meeting requisite technical
and scientific requirements, (2) expanding “Category A” to
include master’s and doctoral degrees, and (3) revising the
coursework requirements of “Category B” to be more flexible with
the inclusion of biology courses.178 Category A degrees now include
bioengineering, biological science, environmental engineering,
genetic engineering, genetics, and neuroscience, which are all areas
of science that are highly populated with women. Furthermore, the
additional qualifying biology courses under Category B tend to be
heavily populated by women.179 Finally, inclusion of advanced
degrees helps women by allowing women with scientific graduate
degrees but non-scientific bachelor’s degrees to take the exam.
Previously, for example, a woman with a bachelor’s degree in
English and a doctorate in Biology would not qualify under
Category A. Inclusion of graduate degrees into Category A fixes
this problem.
The USPTO has also created a program to help foster
development of legal skills through experience. This new USPTO
initiative is called the Legal Experience and Advancement Program
176. See Administrative Updates to the General Requirements Bulletin for Admission
to the Examination for Registration to Practice in Patent Cases Before the United States Patent
and Trademark Office, 86 Fed. Reg. 52652 (proposed Sept. 22, 2021).
177. Courtenay C. Brinkerhoff, Will Revised Patent Bar Qualifications Address Low Gender
Diversity?, NAT’L L. REV. (Mar. 22, 2021), https://www.natlawreview.com/article/willrevised-patent-bar-qualifications-address-low-gender-diversity.
178. See U.S. PAT. & TRADEMARK OFF., supra note 66, at 3–7 (showing the different
scientific and technical requirements necessary for Category A, B, and C classifications to
take the patent bar).
179. See supra Figure 1 (showing that more women than men receive biological science
and chemistry degrees at the bachelor’s, master’s, and doctoral level).
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(LEAP).180 The LEAP program allows the PTAB to grant up to 15
minutes of additional argument time to parties that choose to
participate. The only requirement is that the arguing patent agent
or attorney must have three or fewer substantive oral arguments in
any federal tribunal.181
It is not clear that opportunities for less-experienced lawyers
will necessarily translate to opportunities for women or, for that
matter, people of color. But the fact that the USPTO is aware of the
need to spread patent work among a more diverse array of lawyers
is a step in the right direction.
B. Corporations and Law Firms
Corporations and firms have spent decades paying lip service
to gender equality, yet significant progress has not been made.182
Commentators have shown how law firms implemented diversity
initiatives to win subsequent discrimination litigation.183 However,
these same law firms have little incentive to ensure that the strategies
they adopt “make actual and tangible improvements in the
demographic diversity and inclusiveness of their organizations.”184
Most major law firms have made commitments to diversity, but
our data on patent practice suggests that those commitments have
not made a significant difference in some of those firms’ most
high-stakes matters. The literature on diversity in the legal
profession often laments that law firms are quick to tout the value
of inclusion but then engage in strategies that are superficial at best
and treat people as tokens at worst.185 Women regularly report
being required “to go ‘above and beyond’ to get the same
180. Legal Experience and Advancement Program (Leap), U.S. PAT. & TRADEMARK OFF.,
https://www.uspto.gov/patents/ptab/leap (last visited Sept. 2, 2022).
181. See id. (noting that, as of November 18, 2021, the USPTO removed the requirement
that practitioners needed to have seven or fewer years of experience to qualify for LEAP).
182. See Veronica R. Martinez & Gina-Gail S. Fletcher, Equality Metrics, 130 YALE L.J. F.
869, 885–88 (2021) (showing that firms may be implementing diversity efforts that have
empirically proven to be ineffective but are rewarded for doing so).
183. Id. at 888.
184. Id.
185. See, e.g., DESTINY PEERY, PAULETTE BROWN & EILEEN LETTS, AM. BAR ASS’N COMM’N
ON WOMEN IN THE LEGAL PROFESSION, LEFT OUT AND LEFT BEHIND: THE HURDLES, HASSLES,
AND HEARTACHES OF ACHIEVING LONG-TERM LEGAL CAREERS FOR WOMEN OF COLOR at viii
(2020) (“[Women of color] felt that they were often treated as tokens and trotted out to clients
only when it would help the firm look good but not necessarily in ways that helped them
further their own careers.”).
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recognition and respect as their colleagues[,]” that they face
pressure to act feminine and to do undervalued administrative
work, and that they are treated worse than their male colleagues
after taking time off to have children.186 To enact sustained change,
firms’ most powerful lawyers must be willing, at times, to use their
high-profile roles for the career advancement of lawyers who do
not look like them. The problem, of course, is that such a strategy
depends on the will of powerful actors.
To move beyond the status quo, the expectations of and
incentives for those in power must change. For instance, some large
corporations have begun tying annual executive compensation to
explicit, objective diversity and inclusion goals.187 Law firms could
take similar steps. And some have by, for example, eliminating
“origination credits,” which reward powerbrokers with an
essentially indefinite stream of commission-like income from key
clients.188 In that vein, a recent report by the American Bar
Association and the Minority Corporate Counsel Association on
“bias interrupters” provides a clear roadmap, complete with
objective metrics and techniques for furthering diversity in law
firm work assignment and compensation systems.189
Moreover, clients who hire law firms should wield their
economic power to require women to hold positions of
responsibility when it comes to the client’s case.190 Some clients
have started to exercise that power of the purse, withholding legal
spending from firms that do not meet diversity and inclusion
requirements, requiring teams to consist of a specified percentage
of women and people of color, and giving bonuses to firms when
their legal teams meet diversity goals.191 The general counsel of

186. JOAN C. WILLIAMS ET AL., AM. BAR ASS’N COMM’N ON WOMEN IN THE PROFESSION &
MINORITY CORP. COUNSEL ASS’N, YOU CAN’T CHANGE WHAT YOU CAN’T SEE: INTERRUPTING
RACIAL & GENDER BIAS IN THE LEGAL PROFESSION 7–8 (2018), https://www.mcca.com/wpcontent/uploads/2018/09/You-Cant-Change-What-You-Cant-See-Executive-Summary.pdf.
187. See Carlos, supra note 168.
188. See Irene Liu, Robin Preble & Megan Redmond, Strategies to Help Close IP Law’s
Long-Standing Gender Gap, LAW360 (Apr. 19, 2022, 5:12 PM), https://www.law360.com/
ip/articles/1483932.
189. WILLIAMS ET AL., supra note 186, at 18–21, 25–28.
190. See STEPHANIE A. SCHARF & ROBERTA D. LIEBENBERG, AM. BAR ASS’N, FIRST CHAIRS
AT TRIAL: MORE WOMEN NEED A SEAT AT THE TABLE 16 (2015).
191. Lynn S. Scott, Moving the Needle—We Can’t Give Up, LAW PRAC. TODAY (May 14,
2019), https://www.lawpracticetoday.org/article/moving-needle-cant-give.
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Coca-Cola, for example, was recently in the news for requiring the
company’s law firms “to give a portion of work to Black attorneys
specifically and withholding a nonrefundable 30% of fees from
those that fail to meet diverse staffing metrics.”192
To effect meaningful change, clients must be willing to make
good on their promise to make engagement decisions based on
whether firms meet benchmarks of diversity. Law firms have
reported being “frustrated by clients who asked for detailed
information on diversity and then failed to follow up or to reward
firms that had performed well.”193
C. Lessons from the USPTO
A final place we might look for reform ideas is the USPTO—not
so much its regulatory positions (discussed in section V.A above),
but how the agency works on the ground. As our empirical study
makes clear, patent examiners at the USPTO are comprised roughly
equally of men and women. Additionally, their promotion and
tenure schedules are about equal. Accordingly, the private sector
might enhance diversity by doing some of what the USPTO is
already doing. Important strategies might include: telework,
flexible schedules, and parental leave, among others.
1. Telework and Flexible Schedules
Since 1997, the USPTO has allowed some of its employees a
telework option.194 In 2012, the USPTO launched its Telework
Enhancement Act Pilot Program (TEAPP), which allowed USPTO
employees to work “throughout the country and waive
government paid costs for required travel back to headquarters.”195
This program has led to increased productivity and higher retention

192. Ruiqi Chen, Coke GC Tired of ‘Good Intentions,’ Wants Firm Diversity Now,
BLOOMBERGLAW (Jan. 28, 2021), https://news.bloomberglaw.com/business-and-practice/
coke-gc-tired-of-good-intentions-wants-law-firm-diversity-now.
193. DEBORAH L. RHODE, THE TROUBLE WITH LAWYERS 80 (2015).
194. See U.S. PAT. & TRADEMARK OFF., 2018 TELEWORK ANNUAL REPORT,
https://www.uspto.gov/sites/default/files/documents/Telework_Annual_Report_2018%205
08%20Compliant.pdf [hereinafter 2018 TELEWORK ANNUAL REPORT].
195. U.S. PAT. & TRADEMARK OFF., TELEWORK ENHANCEMENT ACT PILOT PROGRAM 1 (TEAPP),
https://www.uspto.gov/sites/default/files/documents/TEAPP%202020%20Fact%20Sheet.pdf.
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rates as well as increased employee morale.196 In 2018, there were
11,093 teleworkers and 8,824 of them were patent teleworkers.197
The USPTO also allows its examiners to have flexible schedules.
Flextime schedules allow for employees to arrive as early as 5:30
am or as late as 11:30 am.198 Furthermore, the flexible schedule
allows for a “4/10 plan” that allows an employee to work 10 hours
a day for only four days a week.199 Another work option is the
“5/4/9 plan” which allows for eight nine-hour days, plus one
eight-hour day with one day off during each pay period.200
Since many women are the primary care providers for their
family, the ability to work from home is an advantage that cannot
be understated. Countless studies confirm that women remain
much more likely to take time away from their careers to engage in
dependent care than men.201 And decades of scholarship have
documented the costs to people who take on care of relatives and
dependents202 as well as how the value and importance of that care

196. Id.
197. See 2018 TELEWORK ANNUAL REPORT, supra note 194, at 6 (showing the 11,093
teleworkers represent 94.20% of the positions that are telework eligible and that the 8,824
patent teleworkers represent 94.01% of patent positions that are telework eligible).
198. Work-life balance, U.S. PAT. & TRADEMARK OFF, https://www.uspto.gov/jobs/
why-choose-us/work-life-balance (last visited Sept. 2, 2022).
199. Id.
200. Id.
201. Both men and women report dissatisfaction with long hours that mean less time
with family. But a recent study of legal careers fifteen years after law school graduation
found that “[a]lthough men’s incomes remain high relative to the women, their satisfaction
with the family has declined steadily . . . while women’s satisfaction with the family has
remained higher and roughly constant.” The study thus concludes on the somewhat
dispiriting note that “[i]t seems that the non-traditional roles for men are becoming even less
attractive.” Kenneth G. Dau-Schmidt & Kaushik Mukhopadhaya, Men and Women of the
Bar: A Second Look at the Impact of Gender on Legal Careers 86 (June 15, 2022) (unpublished
manuscript), https://ssrn.com/abstract=3745044.
202. A long line of feminist and family law scholarship has identified the means
by which care work is excluded from the market. This exclusion rests on gendered
expectations of what labor family members should provide as acts of altruism and gendered
expectations of parents, partners, and children. See, e.g., Patricia Smith, Family Responsibility
and the Nature of Obligation, in KINDRED MATTERS: RETHINKING THE PHILOSOPHY OF THE
FAMILY 44–46 (Diana Tietjens Meyers, Kenneth Kipnis & Cornelius F. Murphy, Jr. eds. 1993).
These expectations, many have observed, affirm the societal resistance to mixing economic
exchange and intimacy. See, e.g., ARLIE HOCHSCHILD, THE OUTSOURCED SELF: INTIMATE LIFE
IN MARKET TIMES 22 (2012); Jill Hasday, Intimacy and Economic Exchange, 119 HARV. L. REV.
491, 492 (2005).
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is perpetually discounted.203 Teleworking combined with a flexible
work schedule results in removing significant structural barriers
for caregivers, who are overwhelmingly women. These options
help women to advance their careers while also allowing them to
act as the primary caregiver.
This benefit may be more widely adopted since the COVID-19
pandemic has allowed many workers to reap the benefits of
telework. The USPTO telework model is likely to be adopted by
many private firms, which will allow many primary caregivers to
work full-time jobs while also taking care of their families.204
Yet the promise of connection and work through online
platforms could also reinforce inequalities that already exist.
Since the pandemic began, women have exited the labor force at
much higher rates than men.205 Women, and especially women of
color, have been acutely burdened by the closure of schools,
daycares, and elder care facilities.206 The result could be that those
without caretaking responsibilities remain best positioned to take
advantage of new opportunities. Likewise, it is far from clear how
more flexible working arrangements will affect career
advancement. Though firms may have stated policies that allow

203. See, e.g., Katharine Silbaugh, Commodification and Women’s Household Labor, 9 YALE
J. L. & FEMINISM 81, 82 (1997); MARGARET BRINIG, FROM CONTRACT TO COVENANT: BEYOND
THE LAW AND ECONOMICS OF THE FAMILY 22 (2000); MARTHA ALBERTSON FINEMAN, THE
AUTONOMY MYTH: A THEORY OF DEPENDENCY 22 (2004); Naomi Schoembaum, The Law of
Intimate Work, 90 WASH. L. REV. 1167, 1168 (2015); Meredith Harbach, Childcare, Vulnerability,
and Resilience, 37 YALE L. & POL’Y REV. 459, 460 (2019).
204. See Chiara Criscuolo, Peter Gal, Timo Leidecker, Francesco Losma & Giuseppe
Nicoletti, Telework After COVID-19: Survey Evidence from Managers and Works on Implications for
Productivity and Well-Being, OECD GLOB. F. ON PRODUCTIVITY, https://oecdecoscope.blog/
2021/07/28/telework-after-covid-19-survey-evidence-from-managers-and-workers-onimplications-for-productivity-and-well-being/?print=pdf.
205. Kathryn A. Edwards, Women Are Leaving the Labor Force in Record Numbers, RAND
BLOG (Nov. 24, 2020), https://www.rand.org/blog/2020/11/women-are-leaving-the-laborforce-in-record-numbers.html. But see Xiumei Dong, COVID-19 Hasn’t Forced an Exodus of
Women from BigLaw, LAW360 (Feb. 25, 2021, 11:35 AM), https://www.law360.com/
pulse/articles/1358490/covid-19-hasn-t-forced-an-exodus-of-women-from-biglaw (reporting
that about 40% of attorneys leaving the 200 largest law firms in 2020 were women, “a
percentage that is consistent with results from the past three years”).
206. Claire Cain Miller, When Schools Closed, Americans Turned to Their Usual Backup Plan:
Mothers, N.Y. TIMES (Nov. 17, 2020), https://www.nytimes.com/2020/11/17/upshot/schoolsclosing-mothers-leaving-jobs.html; Steven Brown, How COVID-19 Is Affecting Black and
Latino Families’ Employment and Financial Well-Being, URB. INST. (May 6, 2020),
https://www.urban.org/urban-wire/how-covid-19-affecting-black-and-latino-familiesemployment-and-financial-well-being.
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flexibility, those who can be physically present in the office the
most might reap the greatest professional rewards.207
2. Parental Leave
The USPTO has a relatively generous parental leave program
for their non-probationary employees. This program gives a parent
up to six months of leave after a baby is born or adopted.208 This
leave can be used in combination with sick leave, annual leave,
compensatory time, and leave without pay. Leave time can be used
continuously or intermittently.
Additionally, under the Family Medical Leave Act (FMLA), an
employee with at least one year of federal government service can
take up to twelve weeks of leave without pay. Accordingly, an
employee could take a continuous nine-month leave of absence
after the birth or adoption of a child.209 Finally, an employee can
earn up to 160 hours of compensatory time before the baby is born
that may be used after the baby is born.210
Of course, most large law firms also offer leave, flexible hours,
or part-time status for new parents. But accommodation of care
arrangements will only go so far if the benchmarks of how one succeeds
in the long term do not change.211 Many of the accommodations
207. For a general discussion of the challenges and possibilities of remote working
arrangements at law firms, see Manar Morales, 5 Steps For Law Firms Rethinking Flexible Work
Post-COVID, LAW360 (May 14, 2021), https://www.law360.com/articles/1383234/5-stepsfor-law-firms-rethinking-flexible-work-post-covid.
208. POPA Help Guide for Maternity/Paternity Issues, Non-Probationary Employees, U.S.
PAT. & TRADEMARK OFF., http://popa.org/static/media/uploads/uploads/POPA_HELP
_GUIDE_FOR_MAT_PAT_NONPROB_01152015.pdf (last visited Sept. 2, 2022).
209. This would include six months under the USPTO maternity/paternity policy and
twelve weeks under FMLA. Id.
210. Up to 160 hours may be carried over from bi-week to bi-week. Additionally, an
employee can continue to earn and use additional hours of maternity/paternity
compensatory time after the baby is born or placed for adoption for the first six months after
the birth or placement. This program allows the employee to use compensatory time instead
of leave without pay. Id.
211. Indeed, a more trenchant critique of current reform strategies, such as efforts to
facilitate a “work-life balance,” is that they do little to upend the markets (or the neo-liberal
impulse to help those markets expand without limit) that thrive on and exploit unpaid
dependency work. See Nancy Fraser, Between Marketization and Social Protection: Resolving the
Feminist Ambivalence, in FORTUNES OF FEMINISM: FROM STATE-MANAGED CAPITALISM TO
NEOLIBERAL CRISIS 227–42 (2013); see also Nancy Fraser, Contradictions of Capital and Care, 100
NEW LEFT REV. 1, 1 (2016) (“[The crisis of care,] often linked to ideas of ‘time poverty,’ ‘family-
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intended to create flexibility operate, in practice, as penalties that have
detrimental impacts on women’s career advancement.212 Women
might fare better if there were greater state and private investments
in dependent care and paid family leave, to name two oftenproposed reforms.213
CONCLUSION
It is worth noting that the gendered nature of patents and what
is patented may affect who is interested in the subject. The legal
definition of what is patentable is not objective, is socially
constructed, and, therefore, is “open to change.”214 As one scholar
put it, “we need to stop talking about [women in STEM] and
instead focus on why women need to be in STEM in order to
partake” in the patent system.215 The “gendered” nature of the laws
and regulations governing the patent system could certainly affect
women’s interest in entering patent law.216
work balance,’ and ‘social depletion,’ . . . refers to the pressures from several directions that
are currently squeezing a key set of social capacities: those available for birthing and raising
children, caring for friends and family members, maintaining households and broader
communities, and sustaining connections more generally. Historically, these processes of
‘social reproduction’ have been cast as women’s work. . . . Without it there could be no
culture, no economy, no political organization. No society that systematically undermines
social reproduction can endure for long. Today, however, a new form of capitalist society is
doing just that. The result is a major crisis, not simply of care, but of social reproduction in
this broader sense.”) (internal grammar altered).
212. DEEPALI BAGATI, CATALYST REPORT, WOMEN OF COLOR IN U.S. LAW FIRMS 3 (2009)
(“Women lawyers perceived existing flexibility options within law firms as detrimental to
their careers.”).
213. The assumption of care as an altruistic service relieves the state from responsibility
to provide stronger support for families. In this regard, theorizing on vulnerability, led by
Martha Fineman, is instructive. Vulnerability analysis “provides a means of interrogating
the institutional practices that produce the identities and inequalities in the first place.”
Martha Fineman, The Vulnerable Subject: Anchoring Equality in the Human Condition, 20 YALE
J.L. & FEM. 1, 16 (2008). By describing the inevitable and universal condition of human
vulnerability—the “risks of harm, injury and misfortune that are constant, complex,
particular, and out of our control”—Fineman argues for state action that allows people, and
institutions, to build resilience to those risks. Id. at 266–69, 272.
214. JENNIFER C. LAI, PATENT LAW AND WOMEN: TACKLING GENDER BIAS IN
KNOWLEDGE GOVERNANCE 194 (2021).
215. Id.
216. There is a rich literature critiquing patent law doctrine from a feminist perspective.
For a sample, see Malla Pollack, Towards a Feminist Theory of the Public Domain, or Rejecting
the Gendered Scope of the United States Copyrightable and Patentable Subject Matter, 12 WM. &
MARY J. WOMEN & L. 603 (2006); Dan L. Burk, Do Patents Have Gender?, 19 AM. U. J. GENDER,
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Moreover, although there are more women entering STEM,
there is great inequity in who those women are “in terms of their
racial, ethnic, cultural and social backgrounds.”217 Giving women
the opportunity to succeed as well as removing embedded
structural barriers will be necessary to achieve gender equality in
patent law. This study helps refute the pipeline argument at least
with respect to the pharmaceutical field. Simply increasing the
number of women who graduate with science degrees will likely
not increase the number of patent prosecutors or patent litigators
in the private sector in the pharmaceutical field.
To significantly improve gender diversity in the legal
workplace, law firm clients must demand more from their legal
counsel. Clients will likely have to drive this change because law
firms seem unwilling or unable to achieve those results alone.
Solutions may include programs that reduce legal fees for services
provided by firms that do not meet diversity goals or simply
changing law firms that refuse to commit to diversity and equity.
Alternatively, clients could award bonuses to firms who meet
diversity goals and provide opportunities to their minority
members. In short, tying law firm profitability explicitly to the
achievement of diversity and inclusion218 may be the best way to
incentivize greater diversity at the patent bar.

SOC. POL’Y & L. 881 (2011). For feminist critiques in other areas of intellectual property law,
see, e.g., Ann Bartow, Likelihood of Confusion, 41 SAN DIEGO L. REV. 721, 816–17 (2004); Carys
Craig, Reconstructing the Author-Self: Some Feminist Lessons for Copyright Law, 15 AM. U. J.
GENDER, SOC. POL’Y & L. 207, 207 (2007).
217. LAI, supra note 214, at 196.
218. See supra note 191.
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